: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Bacterial Infections and Mycoses

Free Subscription

Articles published in J Antimicrob Chemother
Retrieve available abstracts of 526 articles:
HTML format

Single Articles

February 2026

RODRIGUEZ-VILLODRES A, Rodriguez-Lozano J, Mir-Cros A, Chueca N, et al
Comparative activity of established versus new-generation beta-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study.
J Antimicrob Chemother. 2026;81:dkag034.
PubMed Abstract available

KARAKONSTANTIS S, Tziolos RN, Paneta M, Kritsotakis EI, et al
Global and regional prevalence of metallo-beta-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis.
J Antimicrob Chemother. 2026;81:dkag037.
PubMed Abstract available

THORINGTON R, Barairo N, Peterson SW, Lourenco L, et al
Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017-24.
J Antimicrob Chemother. 2026;81:dkag007.
PubMed Abstract available

SAADE A, Pilmis B, Jacquier H, Lafaurie M, et al
Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study.
J Antimicrob Chemother. 2026;81:dkag021.
PubMed Abstract available

LIN T, Senneville E, Hennart B, Valentin B, et al
Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500 mg at days 1, 15 and 43 in bone and joint or cardiovascular infection.
J Antimicrob Chemother. 2026;81:dkag039.
PubMed Abstract available

MASSACCI FR, Simoni S, Albini E, D'achille G, et al
Tn7860, a novel chromosomal pseudo-compound transposon carrying the OptrA gene in Enterococcus faecalis.
J Antimicrob Chemother. 2026;81:dkag046.
PubMed

CHEN S, Wei Y, Wang Q, Li Y, et al
Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019-24).
J Antimicrob Chemother. 2026;81:dkag016.
PubMed Abstract available

KIM SH, Kim HM, Chung DR, Ko JH, et al
In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm.
J Antimicrob Chemother. 2026;81:dkag031.
PubMed Abstract available

YAMANAKA N, Takahashi H, Takahashi N, Saito H, et al
Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates.
J Antimicrob Chemother. 2026;81:dkag017.
PubMed Abstract available

GATTI M, Rinaldi M, Laici C, Ambretti S, et al
Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of orthotopic liver transplant recipients.
J Antimicrob Chemother. 2026;81:dkag009.
PubMed Abstract available

FUKUDA D, Powell D, Mulgirigama A, Vojtek I, et al
Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future.
J Antimicrob Chemother. 2026;81:dkag054.
PubMed Abstract available

CIACCIO L, Donnan PT, Parcell BJ, Marwick CA, et al
Impact of COVID-19-related healthcare changes on antibiotic resistance in clinical Escherichia coli isolates: interrupted time series analyses in Scotland, UK.
J Antimicrob Chemother. 2026;81:dkag049.
PubMed Abstract available

ROTUNDO S, Russo A, Morena R, Garofalo E, et al
Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bacterial bloodstream infections: a retrospective cohort study.
J Antimicrob Chemother. 2026;81:dkag056.
PubMed Abstract available

CHASTAIN DB, Anderson DT, Eudy J, Henao-Martinez AF, et al
Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation.
J Antimicrob Chemother. 2026;81:dkag055.
PubMed Abstract available

January 2026

COLE MJ, Doumith M, Vickers A, Alexander S, et al
In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates.
J Antimicrob Chemother. 2026;81:dkag001.
PubMed Abstract available

NIJHUIS J, Jansen AME, Wolfs TFW, Muilwijk EW, et al
Real-world evaluation of isavuconazole in children with cancer.
J Antimicrob Chemother. 2026;81:dkaf485.
PubMed Abstract available

SWEENEY EL, Tickner JA, Ertl NG, Bauer MJ, et al
Rapid molecular diagnostics for detection of extensively drug-resistant Salmonella Typhi.
J Antimicrob Chemother. 2026;81:dkaf481.
PubMed Abstract available

CHAVANET P, Matheux A, Sixt T, Barbet J, et al
Penetration of daptomycin in cerebrospinal fluid during pneumococcal meningitis.
J Antimicrob Chemother. 2026;81:dkaf474.
PubMed Abstract available

ZHANG X, Xie Y, Liu F, Cheng Z, et al
Simulated lung exposure in pneumonia patients to evaluate the antibacterial capacity and resistance suppression of clinical tigecycline regimens against carbapenem-resistant Acinetobacter baumannii.
J Antimicrob Chemother. 2026;81:dkaf477.
PubMed Abstract available

WU M, Li J, Zhou Z, Chen Y, et al
Research progress on resistance mechanisms and clinical efficacy of tigecycline against Klebsiella pneumoniae.
J Antimicrob Chemother. 2026;81:dkaf504.
PubMed Abstract available

STURM PDJ, Van Niekerk JM, Lestrade PPA, Peters CJA, et al
Prevalence of macrolide resistance in Mycoplasma pneumoniae in The Netherlands.
J Antimicrob Chemother. 2026;81:dkaf475.
PubMed Abstract available

DWIBEDY SK, Padhy I, Mohapatra SS
A comprehensive analysis of the mutational landscape determining polymyxin resistance in Klebsiella pneumoniae.
J Antimicrob Chemother. 2026;81:dkaf503.
PubMed Abstract available

ZHUO J, Xu J, Chi Y, Zhang N, et al
Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies.
J Antimicrob Chemother. 2026;81:dkaf495.
PubMed Abstract available

MIELKO-NIZIALEK KA, Jablonski S, Wisniewski J, Milczewska J, et al
Antibiotic resistance of Pseudomonas aeruginosa strains-intracellular metabolomics analysis.
J Antimicrob Chemother. 2026;81:dkaf453.
PubMed Abstract available

MAERTENS J, Birne R, Felton T, Neofytos D, et al
Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations.
J Antimicrob Chemother. 2026;81:dkaf473.
PubMed Abstract available

SAAD BAA, Volpe-Chaves CE, de Oliveira CTF, Conte BS, et al
The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae: a systematic review.
J Antimicrob Chemother. 2026;81:dkaf476.
PubMed Abstract available

WANG X, Yin X, Liu Y, Jin Y, et al
Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints.
J Antimicrob Chemother. 2026;81:dkaf502.
PubMed Abstract available

TASCINI C, Bianco G, Bonomo RA, Gaibani P, et al
In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates.
J Antimicrob Chemother. 2026;81:dkaf467.
PubMed Abstract available

MCCRACKEN M, Lerminiaux N, Adam HJ, Baxter M, et al
Enterococcus faecium harbouring vanA, optrA and cfr(D) on a linear plasmid in Canada: a CANWARD surveillance case.
J Antimicrob Chemother. 2026;81:dkaf478.
PubMed Abstract available

WANG X, Zhang H, Song S, Tang X, et al
Impact of extracorporeal membrane oxygenation modes on voriconazole exposure in critically ill patients.
J Antimicrob Chemother. 2026;81:dkaf501.
PubMed Abstract available

NUCCI M, Maertens J
Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies.
J Antimicrob Chemother. 2026;81:dkag010.
PubMed Abstract available

MACPHAIL A, Attwood LO, Rogers BA
Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
J Antimicrob Chemother. 2026;81:dkaf471.
PubMed Abstract available

NIELSEN MBD, Mikkelsen MKD, Rasmussen HC, Hvistendahl MA, et al
Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics.
J Antimicrob Chemother. 2026;81:dkaf487.
PubMed Abstract available

WILSON RC, Gilchrist MJ, Cele R, d'Arc S, et al
Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study.
J Antimicrob Chemother. 2026;81:dkaf484.
PubMed Abstract available

DE HOOP-SOMMEN MA, Freriksen JJM, van der Heijden JEM, Jacobs J, et al
Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents.
J Antimicrob Chemother. 2026;81:dkaf463.
PubMed Abstract available

DANIELS CN, Martin BK, Nahar KS, Rahman KM, et al
Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae.
J Antimicrob Chemother. 2026;81:dkaf493.
PubMed Abstract available

SHAH S, Peng L, Clarke LG, Balasubramani GK, et al
Evaluating hypoalbuminaemia thresholds associated with delayed blood sterilization among patients receiving cefazolin or antistaphylococcal penicillins for MSSA bacteraemia.
J Antimicrob Chemother. 2026;81:dkaf498.
PubMed Abstract available

LIU Y, Zhang SS, Chen JH, Zhu JW, et al
Biomarker-informed PBPK modelling of meropenem in paediatric severe pneumonia: implications for target-site PK/PD.
J Antimicrob Chemother. 2026;81:dkaf500.
PubMed Abstract available

GEORGIOU PC, Siopi M, Tsala M, Lagarde C, et al
Pharmacodynamic studies of taniborbactam (VNRX-5133) combined with cefepime against beta-lactamase-producing Gram-negative bacteria in a neutropenic murine thigh infection model.
J Antimicrob Chemother. 2026;81:dkaf431.
PubMed Abstract available

MELIEFSTE HM, Mudde SE, Ammerman NC, Bexkens ML, et al
Towards enhanced translational value: preclinical drug activity testing against actively multiplying, nutrient-starved and pellicle biofilm-embedded Mycobacterium abscessus.
J Antimicrob Chemother. 2026;81:dkaf468.
PubMed Abstract available

TALIANU A, Fraser-Krauss O, Bolton W, Ming D, et al
Artificial intelligence for improving decision-making in bacterial infection management: a narrative review.
J Antimicrob Chemother. 2026;81:dkaf470.
PubMed Abstract available

RARO OHF, Findlay J, Poirel L, Decousser JW, et al
In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes.
J Antimicrob Chemother. 2026;81:dkaf462.
PubMed Abstract available

AHLSTRAND J, Maatouk I, Doanh LH, Girdthep N, et al
High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-24.
J Antimicrob Chemother. 2026;81:dkaf452.
PubMed Abstract available

MONTERO MM, Fernandez-Munoz A, Domene-Ochoa S, Castaneda S, et al
Preventing resistance development in infections by OXA beta-lactamase-producing Pseudomonas aeruginosa: correlating clinical outcomes with hollow-fibre model input.
J Antimicrob Chemother. 2026;81:dkaf464.
PubMed Abstract available

PATTERSON-FAHY K, Carter R, Bell SC, Evans IES, et al
In vitro efficacy of sulbactam/durlobactam combined with beta-lactam antibiotics in Australian Mycobacterium abscessus isolates.
J Antimicrob Chemother. 2026;81:dkaf441.
PubMed Abstract available

HUANG Y, Truelson KA, Stewart IA, O'Doherty GA, et al
Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus.
J Antimicrob Chemother. 2026;81:dkaf433.
PubMed Abstract available

ZHONG Y, Hope W, Buchan I, Velluva A, et al
Machine learning for personalized antimicrobial susceptibility breakpoints.
J Antimicrob Chemother. 2026;81:dkaf419.
PubMed Abstract available

SHASTRI P, Bains G, Henriksen AS, Karas A, et al
Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes.
J Antimicrob Chemother. 2026;81:dkaf407.
PubMed Abstract available

MUDDE SE, Meliefste HM, Klaassen CHW, Ammerman NC, et al
Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies.
J Antimicrob Chemother. 2026;81:dkaf413.
PubMed Abstract available

SINGH S, Boorgula GD, Nguyen MH, Daley CL, et al
Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease.
J Antimicrob Chemother. 2026;81:dkaf405.
PubMed Abstract available

MENDOZA-PALOMAR N, Simo Nebot S, Roig-Soria L, Alonso Garcia L, et al
Real-life use of isavuconazole in Spanish children and adolescents.
J Antimicrob Chemother. 2026;81:dkaf394.
PubMed Abstract available

DUTKIEWICZ M, Jousset AB, de Swardt H, Rezzoug I, et al
In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales.
J Antimicrob Chemother. 2026;81:dkaf440.
PubMed Abstract available

SHAW D, Thakur S, Ghosh A, Dogra S, et al
Efflux-mediated multidrug resistance mechanism in Trichophyton indotineae and Trichophyton rubrum; role of ABC transporters and MFS gene.
J Antimicrob Chemother. 2026;81:dkaf434.
PubMed Abstract available

MOSTAFA R, Mohammed S, Ahmed AS, Aly SA, et al
Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates.
J Antimicrob Chemother. 2026;81:dkaf422.
PubMed Abstract available

HAUSBERGER CF, Peng L, Balasubramani GK, Shields RK, et al
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.
J Antimicrob Chemother. 2026;81:dkaf432.
PubMed Abstract available

VERMA S, Tilak R, Singh G, Singh S, et al
Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights.
J Antimicrob Chemother. 2026;81:dkaf420.
PubMed Abstract available

GOH M, Eisenkraft Klein D, Kesselheim AS
The curious constraints on clofazimine.
J Antimicrob Chemother. 2026;81:dkaf430.
PubMed Abstract available

ANDERSSON M, Zimmermann N, Kloft C, Aulin LBS, et al
Antibiotic pharmacodynamics: from MIC to advanced metrics and their applications.
J Antimicrob Chemother. 2026;81:dkaf374.
PubMed Abstract available

BETTUZZI T, Strady C, Diamantis S, Matta M, et al
Differences in prescription for impetigo and cellulitis across years in three European countries.
J Antimicrob Chemother. 2026;81:dkaf400.
PubMed Abstract available

ZHU Z, Hua X, Ke Y
Azithromycin resistance in non-typhoidal Salmonella: a review.
J Antimicrob Chemother. 2026;81:dkaf341.
PubMed Abstract available

December 2025

ZHAO R, Wan P, Huang H, Li Q, et al
Harnessing CRISPR-Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate.
J Antimicrob Chemother. 2025 Dec 24:dkaf442. doi: 10.1093.
PubMed Abstract available

ALEXANDER B, Johnson MD, Lovelace B, Coleman CI, et al
Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis.
J Antimicrob Chemother. 2025 Dec 19:dkaf461. doi: 10.1093.
PubMed Abstract available

TOUATI A, Peuchant O, Weikel CA, Bebear C, et al
In vitro activity of gepotidacin against Chlamydia trachomatis.
J Antimicrob Chemother. 2025 Dec 19:dkaf460. doi: 10.1093.
PubMed

KUIL S, Bavalia R, Boyd A, de Jong M, et al
Local antibiotic resistance surveillance in nursing homes using lot quality assurance sampling: a feasibility study.
J Antimicrob Chemother. 2025 Dec 17:dkaf451. doi: 10.1093.
PubMed Abstract available

UEAPHONGSUKKIT T, Udomkarnjananun S, Vanichanan J, Jutivorakool K, et al
Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients.
J Antimicrob Chemother. 2025 Dec 16:dkaf439. doi: 10.1093.
PubMed Abstract available

CANAS MA, Cuervo G, Garcia-Gonzalez J, Krivak F, et al
In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis.
J Antimicrob Chemother. 2025 Dec 4:dkaf435. doi: 10.1093.
PubMed Abstract available

PALACIOS R, Gomez-Ayerbe C, Martin-Cortes S, Gonzalez-Jimenez A, et al
Post-exposure prophylaxis with doxycycline (DoxyPEP) to prevent STIs in a real-world setting: the PRIDOX study.
J Antimicrob Chemother. 2025;80:3306-3310.
PubMed Abstract available

REZZOUG I, Ouacel K, Droit T, Ronsin S, et al
Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales: an in vitro evaluation of novel beta-lactam/beta-lactamase inhibitor combinations and cefiderocol.
J Antimicrob Chemother. 2025;80:3297-3305.
PubMed Abstract available

FU Y, Fouad A, Roenfanz HF, Nicolau DP, et al
Efficacy of human-simulated aztreonam-avibactam against Stenotrophomonas maltophilia in the neutropenic murine thigh infection model.
J Antimicrob Chemother. 2025;80:3431-3437.
PubMed Abstract available

NEOH CF, Yong MK, Rowley L, Roberts AW, et al
Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial.
J Antimicrob Chemother. 2025;80:3401-3406.
PubMed Abstract available

ZHANG H, Liang B, Tan Z, Wang R, et al
The synergistic activity of tigecycline-based combinations against multidrug-resistant Acinetobacter baumannii-caused bloodstream infections.
J Antimicrob Chemother. 2025;80:3407-3418.
PubMed Abstract available

VAN RHIJN N, White PL
Antifungal treatment strategies and their impact on resistance development in clinical settings.
J Antimicrob Chemother. 2025;80:3208-3226.
PubMed Abstract available

ORENBUCH-HARROCH E, Snoyman G, Nashashibi MA, Temper V, et al
Aztreonam-amoxicillin/clavulanate combination therapy against blaNDM-producing Enterobacterales infections.
J Antimicrob Chemother. 2025;80:3375-3380.
PubMed Abstract available

MULLER SE, Junker S, Rehner J, Forster M, et al
Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant Pseudomonas aeruginosa.
J Antimicrob Chemother. 2025;80:3352-3356.
PubMed Abstract available

SMITH S, Reilly CW, Stewart J, Ragh T, et al
Thrice-weekly post-haemodialysis ceftazidime can achieve adequate pre-dialysis concentrations and clinical cure in patients with melioidosis.
J Antimicrob Chemother. 2025;80:3386-3390.
PubMed Abstract available

PELLEGRINO C, Veronese N, De Santis L, Amendolara A, et al
Frailty Index Laboratory (FI-Lab) as predictor of poor outcomes for intra-hospital multidrug-resistant Klebsiella pneumoniae bloodstream infections: a single-centre retrospective cohort study.
J Antimicrob Chemother. 2025;80:3257-3264.
PubMed Abstract available

BLANCO-MARTIN T, Guzman-Puche J, Hernandez-Garcia M, Munoz-Rosa M, et al
Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes.
J Antimicrob Chemother. 2025;80:3265-3272.
PubMed Abstract available

MA J, van Doodewaerd BR, Biersack B, Verbon A, et al
A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-kappaB inhibitors active against eumycetoma.
J Antimicrob Chemother. 2025;80:3320-3328.
PubMed Abstract available

BALTAS I, Tsakri D, Vourli S, Solanki H, et al
Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales.
J Antimicrob Chemother. 2025;80:3273-3277.
PubMed Abstract available

TANG B, Hu X, Song Y, Liu X, et al
Acquired antimicrobial resistance genes in Bordetella Species: a global genomic analysis.
J Antimicrob Chemother. 2025 Dec 1:dkaf418. doi: 10.1093.
PubMed Abstract available

November 2025

TORUMKUNEY D, Mokaddas E, Weber S, Morrissey I, et al
Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Kuwait and the United Arab Emirates: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

TORUMKUNEY D, Van PH, Thinh LQ, Hawser S, et al
Results from the Survey of Antibiotic Resistance (SOAR) 2020-21 in Vietnam: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

TORUMKUNEY D, Veeraraghavan B, Patil N, Dias M, et al
Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in India: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

TORUMKUNEY D, Keles N, Hasdemir U, Hazirolan G, et al
Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Turkiye: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

TORUMKUNEY D, Slim L, Hammami A, Hawser S, et al
Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Tunisia: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

TORUMKUNEY D, Bratus E, Yuvko O, Pertseva T, et al
Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

TORUMKUNEY D, Nizamuddin S, Morrissey I, Manenzhe R, et al
Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

TORUMKUNEY D, Canton R, Pitart C, Sanguinetti M, et al
Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Italy and Spain: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

MIN P, Yao J, Ruan S, Zhou L, et al
Global phylogeography and genomic characterization of blaNDM-1-positive carbapenem-resistant Acinetobacter soli.
J Antimicrob Chemother. 2025 Nov 24:dkaf437. doi: 10.1093.
PubMed Abstract available

LEE GY, Yang SJ
Co-carriage of the oxazolidinone resistance genes cfr and optrA in a linezolid-resistant Staphylococcus rostri isolate from a pig-farm worker.
J Antimicrob Chemother. 2025 Nov 20:dkaf428. doi: 10.1093.
PubMed

ALMEIDA-SANTOS AC, Tedim AP, Duarte B, Silva LM, et al
Unnoticed spread of linear VanA-plasmids in vancomycin-variable Enterococcus faecium strains across different regions: a diagnostics challenge.
J Antimicrob Chemother. 2025 Nov 20:dkaf409. doi: 10.1093.
PubMed Abstract available

BENSACI MF, Bauer KA, Klinker K, Cota J, et al
Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022-2023).
J Antimicrob Chemother. 2025 Nov 20:dkaf414. doi: 10.1093.
PubMed Abstract available

ASHRIN A, Hagenimana C, Jacquier H, Ourghanlian C, et al
Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium.
J Antimicrob Chemother. 2025 Nov 17:dkaf426. doi: 10.1093.
PubMed Abstract available

LU R, Li X, Yang W, Chen J, et al
In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus: a multicenter study in China.
J Antimicrob Chemother. 2025;80:3011-3020.
PubMed Abstract available

TOYTING-HIRAISHI J, Sato T, Tohyama M, Fujino T, et al
Potential human health risk of carbapenem-non-susceptible Pseudomonas aeruginosa from companion animals.
J Antimicrob Chemother. 2025;80:3043-3056.
PubMed Abstract available

GRAFIA I, Moll-Febrer A, Santillan SJ, Rodrigo C, et al
Multidrug resistance and recurrence in urinary bacteraemia among cancer patients.
J Antimicrob Chemother. 2025;80:3026-3033.
PubMed Abstract available

SOW O, Oueslati S, Ndiaye I, Vanparis O, et al
Molecular insights into carbapenemase-producing Enterobacterales from Senegal.
J Antimicrob Chemother. 2025;80:2989-3000.
PubMed Abstract available

JIANG X, Cao D, Qiu Y, Dong X, et al
Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare.
J Antimicrob Chemother. 2025;80:2954-2957.
PubMed Abstract available

NARONGPUN P, Chanchaithong P, Tanomsridachchai W, Nuanmuang N, et al
Emergence of livestock-associated MRSA clonal complex 398 in Thailand's swine industry.
J Antimicrob Chemother. 2025;80:2912-2917.
PubMed Abstract available

BOYD SE, Wootton M, Howe RA, Livermore DM, et al
Rifampicin as monotherapy for infections caused by Staphylococcus aureus: considerations for not applying 'breakpoints in brackets'.
J Antimicrob Chemother. 2025 Nov 3:dkaf392. doi: 10.1093.
PubMed Abstract available

October 2025

REYNOLDS R, Mushtaq S, Hope R, Horner C, et al
Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

REYNOLDS R, Mushtaq S, Hope R, Horner C, et al
Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

HORNER C, Reynolds R, Mushtaq S, Chaudhry A, et al
Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999-2019).
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

MACGOWAN AP, Reynolds R, Parcell BJ, Livermore DM, et al
Two decades of resistance surveillance by the British Society for Antimicrobial Chemotherapy: design, development, delivery, deficiencies and future directions.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

PARCELL BJ, Horner C, Reynolds R, Allen M, et al
Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project-legacy and future.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

ALLEN M, Reynolds R, Mushtaq S, Nsonwu O, et al
The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

LALOUM I, Bidaud AL, Recalt E, Schwarz P, et al
Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus.
J Antimicrob Chemother. 2025 Oct 27:dkaf393. doi: 10.1093.
PubMed Abstract available

GREGSON A, Mowlaboccus S, Sudeep SM, Rizzo S, et al
Dual beta-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes.
J Antimicrob Chemother. 2025 Oct 17:dkaf377. doi: 10.1093.
PubMed Abstract available

LAI CC, Liu CY, Huang KJ, Huang YT, et al
Global susceptibility profiles and potential resistance mechanisms of ceftazidime-avibactam-resistant, non-carbapenemase-producing carbapenem-resistant Enterobacterales: 2020-23 data from the Antimicrobial Testing Leadership and Surveillance.
J Antimicrob Chemother. 2025 Oct 7:dkaf375. doi: 10.1093.
PubMed Abstract available

YANG J, Jiang T, Zhang M, Xue J, et al
Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones.
J Antimicrob Chemother. 2025;80:2862-2872.
PubMed Abstract available

LARKIN C, Valappil SP, Palanisamy N
Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis.
J Antimicrob Chemother. 2025;80:2609-2621.
PubMed Abstract available

HALIM J, Keane AP, Bouzo J, Aderibigbe T, et al
Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms.
J Antimicrob Chemother. 2025;80:2814-2824.
PubMed Abstract available

ZAGHI I, Cricca M, Roberts JA, Brandolini M, et al
Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria.
J Antimicrob Chemother. 2025;80:2705-2713.
PubMed Abstract available

SMITH DJ, Murphy HR, Benedict K, Dailey Garnes NJM, et al
Trends in antifungal use among hospitalized patients in the USA, 2018-23.
J Antimicrob Chemother. 2025;80:2659-2664.
PubMed Abstract available

KOENIG C, Yi F, Nicolau DP, Asempa TE, et al
In vivo activity of ceftibuten-ledaborbactam oral combination against serine-beta-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model.
J Antimicrob Chemother. 2025;80:2714-2718.
PubMed Abstract available

KLEMENTOVA T, Zakoucka H, Bizova B, Unemo M, et al
Cefixime versus benzathine penicillin G for the treatment of early syphilis-a randomized, controlled open label trial.
J Antimicrob Chemother. 2025;80:2654-2658.
PubMed Abstract available

SKOVMAND S, Norgaard C, Salado-Rasmussen K, Jensen JS, et al
In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium.
J Antimicrob Chemother. 2025;80:2676-2681.
PubMed Abstract available

ONG SWX, Pinto R, Rishu A, Tong SYC, et al
Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial.
J Antimicrob Chemother. 2025;80:2752-2758.
PubMed Abstract available

OUDIANE L, Benyahia M, Salipante F, Dubois A, et al
Clinical impact of the BCID2 and rapid AST VITEK(R) REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study.
J Antimicrob Chemother. 2025;80:2665-2675.
PubMed Abstract available

ROGER C, Allaouchiche B, Quintao De Moraes D, Ulrich Feudjio O, et al
Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia.
J Antimicrob Chemother. 2025;80:2644-2653.
PubMed Abstract available

PATEL S, Mohayya S, Yassin A, Dao J, et al
Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia.
J Antimicrob Chemother. 2025;80:2635-2643.
PubMed Abstract available

September 2025

PINDER C, Lebedinec R, Oliver JD, Birch M, et al
In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species.
J Antimicrob Chemother. 2025 Sep 30:dkaf354. doi: 10.1093.
PubMed Abstract available

CINCOTTA SE, Ostrowsky BE, Howard-Anderson J, Beekmann SE, et al
Treatment preferences by infectious diseases clinicians for carbapenem-resistant Enterobacterales infections.
J Antimicrob Chemother. 2025 Sep 30:dkaf371. doi: 10.1093.
PubMed Abstract available

IACHKINE J, Alexandre K, Marlat C, Briant A, et al
Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched cohort study.
J Antimicrob Chemother. 2025 Sep 30:dkaf370. doi: 10.1093.
PubMed Abstract available

GIARRATANA LR, Pirolo M, Roch FF, Conrady B, et al
Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America.
J Antimicrob Chemother. 2025 Sep 27:dkaf340. doi: 10.1093.
PubMed Abstract available

DARLOW CA, Farrington N, Martson AG, Johnson A, et al
Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis.
J Antimicrob Chemother. 2025 Sep 24:dkaf355. doi: 10.1093.
PubMed Abstract available

WITKOWSKA A, Biedrzycka M, Izdebski R, Literacka E, et al
Assessment of an LC coupled with tandem MS (LC-MS/MS) tool in the detection of antimicrobial resistance mechanisms in Enterobacterales.
J Antimicrob Chemother. 2025 Sep 24:dkaf339. doi: 10.1093.
PubMed Abstract available

XU W, Yan P, Li Y, Sun B, et al
The toxin-antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening.
J Antimicrob Chemother. 2025 Sep 23:dkaf325. doi: 10.1093.
PubMed Abstract available

ELADAWY M, Heslop N, Negus D, Thomas JC, et al
Phenotype-genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt.
J Antimicrob Chemother. 2025 Sep 23:dkaf352. doi: 10.1093.
PubMed Abstract available

YANG P, Liu C, Zheng J, Yi J, et al
Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection.
J Antimicrob Chemother. 2025 Sep 18:dkaf337. doi: 10.1093.
PubMed Abstract available

CUI W, Lu R, Huang S, Ma R, et al
Comparative evaluation of broth microdilution and gradient diffusion methods in Burkholderia cepacia complex susceptibility testing: implications of transitioning to ECV-based interpretation.
J Antimicrob Chemother. 2025;80:2530-2540.
PubMed Abstract available

RACCAGNI AR, Diotallevi S, Lolatto R, Bruzzesi E, et al
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy.
J Antimicrob Chemother. 2025;80:2484-2486.
PubMed Abstract available

ERGUN M, Bruggemann RJM, Alanio A, Bentvelsen RG, et al
Classifying patients with invasive fungal disease: towards a unified case definition?
J Antimicrob Chemother. 2025;80:2337-2343.
PubMed Abstract available

LEE Y, Seong J, Lee JA, Ahn JY, et al
Comparing the mortality of patients with sepsis using empirical piperacillin/tazobactam and cefepime: analysis of the MIMIC-IV database.
J Antimicrob Chemother. 2025;80:2487-2495.
PubMed Abstract available

NAIR S, Barker CR, Patel V, Poh CY, et al
Highly drug-resistant Vibrio cholerae harbouring blaPER-7 isolated from travellers returning to England.
J Antimicrob Chemother. 2025;80:2428-2432.
PubMed Abstract available

MAZZITELLI M, Coppi M, Scaglione V, Paci L, et al
Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae.
J Antimicrob Chemother. 2025;80:2442-2446.
PubMed Abstract available

JACQUEMIN A, Palma F, Duque M, Jousset AB, et al
A novel multilocus sequence typing scheme for Morganella spp.: population structure and introduction of quantitative metric for standardization of MLST scheme.
J Antimicrob Chemother. 2025;80:2391-2398.
PubMed Abstract available

TAN Z, Liang W, Zhang N, Liang B, et al
Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis.
J Antimicrob Chemother. 2025;80:2344-2360.
PubMed Abstract available

IMOLI D, Maingi JM, Mbae C, Kavai SM, et al
Genomic characterization of multidrug-resistant extended-spectrum beta-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya.
J Antimicrob Chemother. 2025;80:2399-2407.
PubMed Abstract available

OLDBERG K, Rasmussen M
Comment on: Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus.
J Antimicrob Chemother. 2025 Sep 2:dkaf320. doi: 10.1093.
PubMed

August 2025

GELE T, Atwine D, Baudin E, Muyindike W, et al
Pharmacokinetics of rifampicin and isoniazid in patients with HIV-tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292-RIFAVIRENZ sub-study.
J Antimicrob Chemother. 2025 Aug 29:dkaf319. doi: 10.1093.
PubMed Abstract available

HAO J, Lu F, Chen P, Ji C, et al
Characterization of blaOXA-542-mediated carbapenem resistance in Acinetobacter baumannii.
J Antimicrob Chemother. 2025 Aug 29:dkaf311. doi: 10.1093.
PubMed Abstract available

LI J, Hou W, Chang J, Tian X, et al
The pivotal role of acnA in linking carbon metabolism to virulence and antimicrobial resistance in methicillin-resistant Staphylococcus aureus.
J Antimicrob Chemother. 2025 Aug 28:dkaf317. doi: 10.1093.
PubMed Abstract available

MCCRACKEN M, Walkty A, Adam HJ, Baxter M, et al
Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6 years of the CANWARD study (2018-23).
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

MATASEJE LF, Lerminiaux N, Lagace-Wiens P, Walkty A, et al
Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007-23).
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

ADAM HJ, Golden AR, Martin I, Baxter MR, et al
Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007-23).
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

BRAHAMI A, Karlowsky JA, McCracken M, Golding GR, et al
Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007-23).
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

WALKTY A, Adam HJ, Baxter M, Karlowsky JA, et al
Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007-23).
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

ZHANEL GG, Baxter MR, Lagace-Wiens P, Walkty A, et al
Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23).
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

ZHANEL GG, Baxter MR, Golden AR, Lagace-Wiens P, et al
Gram-positive pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23).
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

LAGACE-WIENS P, Mataseje L, McCracken M, Walkty A, et al
Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007-23.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

SUN Y, McGiffin D, Ye L, Kostoulias X, et al
Low bacterial metabolism as a central mechanism of antimicrobial resistance and potential therapeutic target of staphylococcal biofilms in ventricular assist device driveline infections.
J Antimicrob Chemother. 2025 Aug 26:dkaf316. doi: 10.1093.
PubMed Abstract available

CERCENADO E, Marin M, Iglesias M, Jimenez L, et al
Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin.
J Antimicrob Chemother. 2025 Aug 21:dkaf308. doi: 10.1093.
PubMed Abstract available

SAMUELSSON T, Lonnermark E, Sundell J, Yilmaz A, et al
Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index.
J Antimicrob Chemother. 2025 Aug 21:dkaf300. doi: 10.1093.
PubMed Abstract available

MANCINI S, Seth-Smith HMB, Kolesnik-Goldmann N, Mermod M, et al
Performance of disc diffusion and gradient strip test on different Mueller-Hinton agar media plates and ComASP(R) and Bruker UMIC(R) Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa
J Antimicrob Chemother. 2025 Aug 18:dkaf301. doi: 10.1093.
PubMed Abstract available

VAN DER FELTZ I, Wen H, Aarnoutse RE, Magis-Escurra C, et al
Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology.
J Antimicrob Chemother. 2025 Aug 14:dkaf274. doi: 10.1093.
PubMed Abstract available

BALAKUNTLA J, Simjee S, Mane SP, Tice G, et al
Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates.
J Antimicrob Chemother. 2025 Aug 7:dkaf296. doi: 10.1093.
PubMed Abstract available

ZENG Q, Huang H, Lu J, Wu L, et al
Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study.
J Antimicrob Chemother. 2025 Aug 7:dkaf295. doi: 10.1093.
PubMed Abstract available

BIERGE P, Gomez-Sanchez I, Garcia de la Maria C, Sanchez-Osuna M, et al
Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium?
J Antimicrob Chemother. 2025 Aug 6:dkaf226. doi: 10.1093.
PubMed Abstract available

ANASTASSOPOULOU C, Panagiotopoulos AP, Ferous S, Tsakris A, et al
Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules.
J Antimicrob Chemother. 2025 Aug 6:dkaf293. doi: 10.1093.
PubMed Abstract available

BASOULIS D, Gkoufa A, Mastrogianni E, Pantazatou A, et al
Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study.
J Antimicrob Chemother. 2025;80:2314-2322.
PubMed Abstract available

POIGNON C, Dortet L, Birer A, Rezzoug I, et al
Characterization of Carbapenemase-producing Enterobacterales isolated from patients returning from Sub-Saharan Africa, France, 2015-2022.
J Antimicrob Chemother. 2025;80:2285-2294.
PubMed Abstract available

KOELE SE, Stoycheva K, Mtweve C, Manyama C, et al
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB.
J Antimicrob Chemother. 2025;80:2305-2313.
PubMed Abstract available

JIN Y, Zhou W, Chen W, Xiao Y, et al
Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections.
J Antimicrob Chemother. 2025;80:2295-2304.
PubMed Abstract available

MOGUET C, Oueslati S, Vanparis O, Cisse L, et al
Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales.
J Antimicrob Chemother. 2025;80:2241-2246.
PubMed Abstract available

BRENCIANI A, Massacci FR, Albini E, Cucco L, et al
Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy.
J Antimicrob Chemother. 2025;80:2280-2284.
PubMed Abstract available

SADER HS, Kimbrough JH, Winkler ML, Castanheira M, et al
Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023).
J Antimicrob Chemother. 2025;80:2070-2079.
PubMed Abstract available

WANG A, Liu P, Wu Y, Ma R, et al
Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa.
J Antimicrob Chemother. 2025;80:2117-2125.
PubMed Abstract available

TANIGUCHI J, Aso S, Matsui H, Fushimi K, et al
Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study.
J Antimicrob Chemother. 2025;80:2194-2202.
PubMed Abstract available

SHAFIQ N, Kumar A, Vohra V, Khuller GK, et al
Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial.
J Antimicrob Chemother. 2025;80:2100-2108.
PubMed Abstract available

July 2025

FERRANDO ML, Saluzzo F, Frederiksen RF, Slettemeas JS, et al
Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium.
J Antimicrob Chemother. 2025 Jul 31:dkaf113. doi: 10.1093.
PubMed Abstract available

MELETIADIS J, Guinea J, Arikan-Akdagli S, Meijer EFJ, et al
A multicentre study for determination of epidemiological cut-off values for Candida auris with EUCAST broth microdilution reference methodology.
J Antimicrob Chemother. 2025 Jul 29:dkaf241. doi: 10.1093.
PubMed Abstract available

LUQUE PAZ D, Turban A, Guerin F, Penven M, et al
Paradoxical interaction between dalbavancin and beta-lactams against endocarditis-associated Enterococcus faecalis clinical isolates.
J Antimicrob Chemother. 2025 Jul 28:dkaf262. doi: 10.1093.
PubMed Abstract available

CHEN X, Ouyang F, Wang N, Liu D, et al
Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo.
J Antimicrob Chemother. 2025 Jul 25:dkaf239. doi: 10.1093.
PubMed Abstract available

NODA M, Furuta A, Yashima S, Yaguchi D, et al
Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance.
J Antimicrob Chemother. 2025 Jul 25:dkaf258. doi: 10.1093.
PubMed Abstract available

DEL MONTE M, Kaleci S, Chester J, Zerbato V, et al
Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study.
J Antimicrob Chemother. 2025 Jul 22:dkaf242. doi: 10.1093.
PubMed Abstract available

MORETO-CASTELLSAGUE C, Gonzalez-Diaz A, Escrihuela-Vidal F, Calvo-Silveria S, et al
In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization.
J Antimicrob Chemother. 2025 Jul 22:dkaf260. doi: 10.1093.
PubMed Abstract available

OU TH, Yang JL, Lin CY, Huang SH, et al
Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection.
J Antimicrob Chemother. 2025 Jul 17:dkaf225. doi: 10.1093.
PubMed Abstract available

SPRUIJTENBURG B, de Groot T, Meijer EFJ
SCY-247, a novel second-generation triterpenoid antifungal, demonstrates high in vitro activity against genetically diverse Candida auris isolates, including FKS1 mutants.
J Antimicrob Chemother. 2025 Jul 17:dkaf240. doi: 10.1093.
PubMed

SINGH S, Adhikari S, Varshney N, Rani C, et al
Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics.
J Antimicrob Chemother. 2025 Jul 15:dkaf233. doi: 10.1093.
PubMed Abstract available

TURICCHI G, Bongiovanni M
Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option?
J Antimicrob Chemother. 2025 Jul 8:dkaf215. doi: 10.1093.
PubMed

VAN DEN BIGGELAAR RHGA, Erdkamp D, de Visser AW, van den Eeden SJF, et al
Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus.
J Antimicrob Chemother. 2025 Jul 1:dkaf198. doi: 10.1093.
PubMed Abstract available

THORLEY EV, Hatch J, Li M, Mashida SN, et al
Liposomal amphotericin B prophylaxis in paediatrics: a systematic review.
J Antimicrob Chemother. 2025;80:1792-1802.
PubMed Abstract available

RANGANATH N, Tabaja H, Nair VO, Dumais M, et al
Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections.
J Antimicrob Chemother. 2025;80:2016-2024.
PubMed Abstract available

CHUA TP, Danielewski J, Bradshaw CS, Machalek DA, et al
A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro.
J Antimicrob Chemother. 2025;80:2044-2050.
PubMed Abstract available

GONCALVES AB, Alves V, Neves I, Read A, et al
Real-time FT-IR typing of Klebsiella pneumoniae: a flexible and rapid approach for outbreak detection and infection control.
J Antimicrob Chemother. 2025;80:2025-2031.
PubMed Abstract available

PARANOS P, Siopi M, Papanikolaou E, Vourli S, et al
Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations.
J Antimicrob Chemother. 2025;80:1997-2006.
PubMed Abstract available

KRZYZEK P, Opalinska A, Migdal P, Tusiewicz K, et al
Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori.
J Antimicrob Chemother. 2025;80:2032-2043.
PubMed Abstract available

ROSCA AS, Chaponda EB, Beckers T, De Koning HP, et al
Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus.
J Antimicrob Chemother. 2025;80:1972-1979.
PubMed Abstract available

KOONG J, Hall RM, Hamidian M
Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875.
J Antimicrob Chemother. 2025;80:1988-1992.
PubMed Abstract available

ATTWOOD MLG, Noel A, Griffin P, Racine E, et al
In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains.
J Antimicrob Chemother. 2025;80:1942-1946.
PubMed Abstract available

DAVIDSON HC, Yau T, Dunstan I, Houston A, et al
Early use of the novel antifungal rezafungin: a case series and literature review.
J Antimicrob Chemother. 2025;80:1885-1892.
PubMed Abstract available

June 2025

RINALDI M, Rancan I, Malerba F, Gatti M, et al
Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes.
J Antimicrob Chemother. 2025 Jun 19:dkaf197. doi: 10.1093.
PubMed Abstract available

ZHENG YD, Xu J, Wu J, Zhong T, et al
Oleanolic acid derivative bardoxolone combats multidrug-resistant Staphylococcus aureus by destroying cell membrane and pyruvate metabolism pathway.
J Antimicrob Chemother. 2025 Jun 10:dkaf190. doi: 10.1093.
PubMed Abstract available

KIHLBERG P, Bech Johannesen T, Stegger M, Cajander S, et al
Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia.
J Antimicrob Chemother. 2025 Jun 10:dkaf187. doi: 10.1093.
PubMed Abstract available

EL NAGAR A, Dewe TCM, Broadfoot F, Teale C, et al
Decreasing antimicrobial resistance in representative UK livestock species was associated with reduced total sales of antimicrobials in the last decade.
J Antimicrob Chemother. 2025 Jun 5:dkaf145. doi: 10.1093.
PubMed Abstract available

EDSLEV SM, Laurent F, Mansson E, Johannesen TB, et al
Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France.
J Antimicrob Chemother. 2025 Jun 3:dkaf166. doi: 10.1093.
PubMed Abstract available

MA J, Eadie K, Konings M, Fahal A, et al
Ibrexafungerp prolongs survival and reduces the eumycetoma grain size in Galleria mellonella infection models of two different causative agents of eumycetoma.
J Antimicrob Chemother. 2025;80:1733-1741.
PubMed Abstract available

HANDAL N, Kaspersen H, Mo SS, Cabanel N, et al
A comparative study of the molecular characteristics of human uropathogenic Escherichia coli collected from two hospitals in Norway and France in 2019.
J Antimicrob Chemother. 2025;80:1707-1715.
PubMed Abstract available

CHEN WP, Chen CL, Siu LK, Chang FY, et al
Antibiotic treatment of Stenotrophomonas maltophilia bacteraemia: does trimethoprim/sulfamethoxazole dose affect clinical outcomes?
J Antimicrob Chemother. 2025;80:1716-1725.
PubMed Abstract available

RODRIGUEZ-VILLODRES A, Soto-Gallego C, Ortiz De La Rosa JM, Rodriguez-Rodriguez M, et al
Impact of the inoculum effect on cefepime activity against AmpC-hyperproducing Enterobacter spp.: insights into resistance mechanisms.
J Antimicrob Chemother. 2025;80:1687-1693.
PubMed Abstract available

CAMPANA-BURGUET A, Latorre-Fernandez J, Eguizabal P, Belles-Belles A, et al
Changing epidemiology of MRSA-CC398 in Spanish hospitals located in areas with different pig farming densities: a 2023 multicentre study.
J Antimicrob Chemother. 2025;80:1577-1586.
PubMed Abstract available

KOCER K, Gopel L, Gisch S, Tueffers L, et al
Detection of a novel SME-6 Carbapenemase in Serratia ureilytica in Germany.
J Antimicrob Chemother. 2025;80:1682-1686.
PubMed Abstract available

SASTRE-ESCOLA E, Ntziora F, Chiurlo M, Martin-Davila P, et al
Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study).
J Antimicrob Chemother. 2025;80:1673-1681.
PubMed Abstract available

ZHANG BL, Li H, Wang WX, Chen XZ, et al
Depolymerase as a potent adjunct to polymyxin for targeting KL160 pandrug-resistant Acinetobacter baumannii in a murine bacteremia model.
J Antimicrob Chemother. 2025;80:1613-1625.
PubMed Abstract available

HAMZE H, Payne M, Stefanovic A, Lowe CF, et al
Helicobacter pylori culture positivity and antimicrobial susceptibility profiles (Vancouver, Canada).
J Antimicrob Chemother. 2025;80:1640-1646.
PubMed Abstract available

ROBSON C, Liu X, Al-Mukhtar O, Wallis SC, et al
Population pharmacokinetics and optimized prophylaxis dosing of cefazolin during transcatheter aortic valve implantation.
J Antimicrob Chemother. 2025;80:1604-1612.
PubMed Abstract available

BITAR M, Le Moigne V, Herrmann JL, Arthur M, et al
In vitro, intracellular and in vivo synergy between amoxicillin, imipenem and relebactam against Mycobacterium abscessus.
J Antimicrob Chemother. 2025;80:1560-1567.
PubMed Abstract available

SARIA P, Doulidis PG, Desvars-Larrive A, Toth AG, et al
Pandemic human-associated extended-spectrum beta-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs.
J Antimicrob Chemother. 2025;80:1573-1576.
PubMed Abstract available

HOLLAND TL, Shorr AF, Overcash JS, Engelhardt M, et al
Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials.
J Antimicrob Chemother. 2025;80:1526-1534.
PubMed Abstract available

FRATONI AJ, Padgett AM, Duffy EM, Nicolau DP, et al
Quantitative performance of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia mode
J Antimicrob Chemother. 2025;80:1552-1559.
PubMed Abstract available

GATTI M, Rinaldi M, Bonazzetti C, Siniscalchi A, et al
A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy use
J Antimicrob Chemother. 2025;80:1543-1551.
PubMed Abstract available

May 2025

CHO H, Park KT
A novel methicillin-resistant Staphylococcus aureus lineage (ST4174) with an uncharacterized SCCmec variant identified in Korean pigs.
J Antimicrob Chemother. 2025 May 31:dkaf178. doi: 10.1093.
PubMed

SHAH S, Clarke LG, Balasubramani GK, Peng L, et al
Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia.
J Antimicrob Chemother. 2025 May 31:dkaf134. doi: 10.1093.
PubMed Abstract available

HAYASHI Y, Takahashi M, Sasaki M, Suzuki K, et al
Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium.
J Antimicrob Chemother. 2025 May 29:dkaf175. doi: 10.1093.
PubMed Abstract available

CANAS MA, Garcia-de-la-Maria C, Garcia-Gonzalez J, Jimenez MP, et al
Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains.
J Antimicrob Chemother. 2025 May 27:dkaf149. doi: 10.1093.
PubMed Abstract available

KRISHNAPRASAD VH, Nayak V, Kumar S
World Health Organisation's Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: 'challenges and opportunities'.
J Antimicrob Chemother. 2025 May 27:dkaf167. doi: 10.1093.
PubMed Abstract available

MORIN A, Le Guen J, Benaboud S, Richebe P, et al
Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis?
J Antimicrob Chemother. 2025 May 26:dkaf165. doi: 10.1093.
PubMed

MOSIICHUK N, Enggren G, Da Silva ZL, Moren AK, et al
Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions.
J Antimicrob Chemother. 2025 May 26:dkaf153. doi: 10.1093.
PubMed Abstract available

HTAIK K, Vodstrcil LA, Plummer EL, Matthews LG, et al
Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium.
J Antimicrob Chemother. 2025 May 22:dkaf142. doi: 10.1093.
PubMed Abstract available

VILLAMARIN M, Fernandez-Hidalgo N, Escola-Verge L
Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre-a counterpoint.
J Antimicrob Chemother. 2025 May 21:dkaf164. doi: 10.1093.
PubMed

BUTSCHEID Y, Frey PM, Pfister M, Pagani L, et al
Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study.
J Antimicrob Chemother. 2025 May 14:dkaf136. doi: 10.1093.
PubMed Abstract available

VERA-YUNCA D, Matias C, Vingsbo Lundberg C, Friberg LE, et al
Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time-kill experiments to a mouse pneumonia model.
J Antimicrob Chemother. 2025 May 9:dkaf140. doi: 10.1093.
PubMed Abstract available

DANNEELS P, Lemaignen A, Lorleac'h A, Talarmin JP, et al
Comment on: Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre.
J Antimicrob Chemother. 2025 May 8:dkaf138. doi: 10.1093.
PubMed

SINGH R, Mukherjee S, Harrision LB, McDermott PF, et al
Cross-resistance to 14-, 15- and 16-membered ring macrolides in Salmonella and Campylobacter.
J Antimicrob Chemother. 2025;80:1445-1452.
PubMed Abstract available

KOELE SE, Heinrich N, De Jager VR, Dreisbach J, et al
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043.
J Antimicrob Chemother. 2025;80:1315-1323.
PubMed Abstract available

ATHANASSA Z, Papakyriakopoulou P, Marquez Megias S, Saitani EM, et al
Population pharmacokinetic model of oral minocycline in critically ill adult patients with ventilator-associated pneumonia.
J Antimicrob Chemother. 2025;80:1420-1426.
PubMed Abstract available

PAIRMAN L, Beh YT, Maher H, Gardiner SJ, et al
A retrospective observational cohort study of oral azithromycin treatment for Legionnaires' disease.
J Antimicrob Chemother. 2025;80:1354-1361.
PubMed Abstract available

PINA-SANCHEZ M, Rua M, Lopez-Causape C, Bilbao I, et al
Ceftazidime-avibactam plus aztreonam cocktail for the treatment of VIM-producing Pseudomonas aeruginosa infections: good enough to have another?
J Antimicrob Chemother. 2025;80:1371-1376.
PubMed Abstract available

SKALLY M, Cafferkey J, Russell M, Mcbrierty L, et al
Screening for carbapenemase-producing Enterobacterales (CPE)-considering the practical implications of molecular results, the value of culture and deciding criteria for resistance.
J Antimicrob Chemother. 2025;80:1402-1406.
PubMed Abstract available

AGGOUN D, Verdonk C, Bleibtreu A, Fekkar A, et al
Prophylaxis against Pneumocystis jirovecii pneumonia and toxoplasmosis with low-dose Trimethoprim-sulfamethoxazole (cotrimoxazole 20/100 mg) in heart transplant patients. The PAPTO-LOCO observational comparative study.
J Antimicrob Chemother. 2025;80:1394-1401.
PubMed Abstract available

THENE L, Floch P, Chagneau CV, Dubois D, et al
In vitro activity of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against clinical isolates of non-aeruginosa Pseudomonas.
J Antimicrob Chemother. 2025;80:1296-1301.
PubMed Abstract available

BAVARO DF, Accurso G, Corcione S, Vena A, et al
Antipseudomonal cephalosporins versus piperacillin/tazobactam or carbapenems for the definitive antibiotic treatment of Pseudomonas aeruginosa bacteraemia: new kids on the ICU block?
J Antimicrob Chemother. 2025;80:1342-1353.
PubMed Abstract available

SINGH N, Dangi B, Johnson JJ, Louie A, et al
Pharmacodynamic assessment of apramycin against Mycobacterium abscessus in a hollow fibre infection model.
J Antimicrob Chemother. 2025;80:1309-1314.
PubMed Abstract available

MATULUKO A, Mantzourani E, Ahmed H, Cannings-John R, et al
Comparison of antibiotic provision associated with acute sore throat symptom management in community pharmacies in Wales and England: a natural policy experiment.
J Antimicrob Chemother. 2025;80:1256-1260.
PubMed Abstract available

VAN DEN BERG S, Sassen SDT, Couet W, Marchand S, et al
The synergistic effect of the combination of polymyxin B and rifampicin in a murine neutropenic thigh infection model with E. coli and K. pneumoniae.
J Antimicrob Chemother. 2025;80:1248-1255.
PubMed Abstract available

April 2025

LOCKE JB, Andes D, Flanagan S, Redell M, et al
Activity of rezafungin against Candida auris.
J Antimicrob Chemother. 2025 Apr 30:dkaf124. doi: 10.1093.
PubMed Abstract available

METARFI Y, Chellal W, Ben Khadda Z, Hoummani H, et al
Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review.
J Antimicrob Chemother. 2025 Apr 21:dkaf126. doi: 10.1093.
PubMed Abstract available

WASSELIN V, Budin-Verneuil A, Rince I, Desriac F, et al
Tetracyclines at subinhibitory concentrations are lethal for NADH peroxidase-deficient mutants of Enterococcus faecium.
J Antimicrob Chemother. 2025 Apr 10:dkaf105. doi: 10.1093.
PubMed Abstract available

TALA-IGHIL T, Royer G, Lepeule R, Fihman V, et al
Clinical features and medical-surgical management overweight the inoculum effect and genotypic characteristics of MSSA in infective endocarditis.
J Antimicrob Chemother. 2025 Apr 10:dkaf115. doi: 10.1093.
PubMed Abstract available

FIFER H, Johnson A
The continuing evolution of antibiotic resistance in Neisseria gonorrhoeae: past, present and future threats to effective treatment.
J Antimicrob Chemother. 2025 Apr 10:dkaf109. doi: 10.1093.
PubMed Abstract available

KANG SW, Jang HM, Chang E, Bae S, et al
Impact of fluoroquinolone exposure on the diagnosis and prognosis of tuberculosis in immunocompromised patients: a propensity-score-matched, competing risk analysis.
J Antimicrob Chemother. 2025 Apr 7:dkaf111. doi: 10.1093.
PubMed Abstract available

YAN T, Wang J, Zhu R, Ma D, et al
Vonoprazan improves the efficacy of bismuth quadruple therapy containing doxycycline and metronidazole as first-line Helicobacter pylori treatment in penicillin-allergic patients: a randomized controlled trial.
J Antimicrob Chemother. 2025;80:927-934.
PubMed Abstract available

WEERDENBURG H, Walker H, Haeusler GM, Cole T, et al
Relationship between posaconazole concentrations and clinical outcomes in paediatric cancer and haematopoietic stem cell transplant recipients.
J Antimicrob Chemother. 2025;80:897-907.
PubMed Abstract available

TELLAPRAGADA C, Dunleavy C, Jonsson P, Giske CG, et al
Decreased susceptibility to cefepime/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2.
J Antimicrob Chemother. 2025;80:1137-1140.
PubMed Abstract available

SHIFERAW MW, Donnelley MA, Thompson GR 3rd
Prevalence of antifungal allergies in the general population.
J Antimicrob Chemother. 2025;80:1080-1083.
PubMed Abstract available

KHANINA A, Singh N, James R, Kong DCM, et al
Assessing the appropriateness of antifungal prescribing: key results from the implementation of a novel audit tool in Australian hospitals.
J Antimicrob Chemother. 2025;80:1127-1136.
PubMed Abstract available

HAENNI M, Murri S, Drapeau A, Rafidinarivo I, et al
Emergence of MRSA ST612 in horses and of MSSA CC398 in cats in France.
J Antimicrob Chemother. 2025;80:1001-1010.
PubMed Abstract available

QIU H, Dai W
Type IV PilD mutant stimulates the formation of persister cells in Pseudomonas aeruginosa.
J Antimicrob Chemother. 2025;80:1031-1036.
PubMed Abstract available

GRAVES ET, Wardlow L, Ogake S, Bazan JA, et al
Comparison of trimethoprim-sulfamethoxazole versus minocycline monotherapy for treatment of Stenotrophomonas maltophilia pneumonia.
J Antimicrob Chemother. 2025;80:988-995.
PubMed Abstract available

JAKUBU V, Cechova M, Musilek M, Malisova L, et al
Amino acid substitutions in PBP3 in Haemophilus influenzae strains, their phenotypic detection and impact on resistance to beta-lactams.
J Antimicrob Chemother. 2025;80:980-987.
PubMed Abstract available

MACGOWAN AP, Griffin P, Attwood MLG, Daum AM, et al
The pharmacodynamics of fosfomycin in combination with meropenem against Klebsiella pneumoniae studied in an in vitro model of infection.
J Antimicrob Chemother. 2025;80:967-975.
PubMed Abstract available

REBELO AR, Bortolaia V, Leekitcharoenphon P, Hansen DS, et al
One day in Denmark: whole-genome sequence-based analysis of Escherichia coli isolates from clinical settings.
J Antimicrob Chemother. 2025;80:1011-1021.
PubMed Abstract available

ZHENG YQ, Li QG, Latge JP, Tang XK, et al
Potential risk of cross-resistance to voriconazole in HIV/AIDS patients with Talaromyces marneffei infection and the mechanisms of the cross-resistance.
J Antimicrob Chemother. 2025;80:976-979.
PubMed Abstract available

March 2025

SCHELLENBERG JJ, Adam HJ, Baxter MR, Karlowsky JA, et al
Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing inva
J Antimicrob Chemother. 2025 Mar 25:dkaf085. doi: 10.1093.
PubMed Abstract available

LANDMAN D, Cherniak M, Gefen O, Michael-Gayego A, et al
Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus.
J Antimicrob Chemother. 2025 Mar 25:dkaf095. doi: 10.1093.
PubMed Abstract available

GOMEZ-VILLEGAS SI, Rincon S, Carvajal LP, Matiz-Gonzalez JM, et al
Validation of a modified rapid test to detect the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus from bloodstream infections in hospitals from North and Latin America.
J Antimicrob Chemother. 2025 Mar 24:dkaf093. doi: 10.1093.
PubMed Abstract available

MANCINI S, Greiner M, Egli A, Nolte O, et al
In vitro susceptibility testing of vancomycin-resistant Enterococcus faecium to fosfomycin.
J Antimicrob Chemother. 2025 Mar 18:dkaf084. doi: 10.1093.
PubMed

SCHRODER D, Cherdtrakulkiat T, Doanh LH, Golparian D, et al
Exceedingly high levels of tetracycline resistance in Neisseria gonorrhoeae in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-2024-doxycycline post-exposure prophylaxis will unlikely impact gono
J Antimicrob Chemother. 2025 Mar 18:dkaf066. doi: 10.1093.
PubMed Abstract available

CINTHI M, Coccitto SN, Simoni S, Gherardi G, et al
The optrA, cfr(D) and vanA genes are co-located on linear plasmids in linezolid- and vancomycin-resistant enterococcal clinical isolates in Italy.
J Antimicrob Chemother. 2025 Mar 17:dkaf082. doi: 10.1093.
PubMed Abstract available

MORRISSEY CO
Diagnosis and management of invasive fungal infections due to non-Aspergillus moulds.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

PAGANO L, Fernandez OM
Clinical aspects and recent advances in fungal diseases impacting human health.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

DONOVAN FM, Fernandez OM, Bains G, DiPompo L, et al
Coccidioidomycosis: a growing global concern.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

ARENDRUP MC, Cordonnier C
Refractory versus resistant invasive aspergillosis.
J Antimicrob Chemother. 2025;80.
PubMed Abstract available

WU S, Zhang L, Luo X, Lin C, et al
In vitro and in vivo antibacterial activity, resistance analysis and molecular docking study of pleuromutilin derivatives against Streptococcus suis.
J Antimicrob Chemother. 2025 Mar 13:dkaf064. doi: 10.1093.
PubMed Abstract available

LIU Q, Zhou X, Du Z, Wang X, et al
Intraventricular injection of eravacycline in the treatment of carbapenem-resistant Acinetobacter baumannii meningitis: a case report.
J Antimicrob Chemother. 2025 Mar 11:dkaf069. doi: 10.1093.
PubMed

LEE SO, Lee S, Park S, Lee JE, et al
In vivo evaluation of cefazolin inoculum effect in the treatment of experimental Staphylococcus aureus pneumonia with cefazolin.
J Antimicrob Chemother. 2025 Mar 4:dkaf065. doi: 10.1093.
PubMed Abstract available

DING J, Hameed HMA, Long L, Zhang J, et al
Correlation between rrs gene mutations and amikacin resistance in Mycobacterium abscessus: implications for fitness cost and clinical prevalence.
J Antimicrob Chemother. 2025;80:746-751.
PubMed Abstract available

CLAUS BOM, De Smedt D, De Cock PA
Therapeutic drug monitoring versus Bayesian AUC-based dosing for vancomycin in routine practice: a cost-benefit analysis.
J Antimicrob Chemother. 2025;80:857-867.
PubMed Abstract available

SAYDAN S, Schwab F, Holstiege J, Batzing J, et al
Surveillance of Clostridioides difficile on hospital admission and outpatient antibiotic use in Germany-a 9 year ecological analysis.
J Antimicrob Chemother. 2025;80:817-824.
PubMed Abstract available

KARADOGAN E, Sertcelik A, Dizman GT, Uzar H, et al
A scoring system to predict resistance to ceftolozane/tazobactam in respiratory isolates of Pseudomonas aeruginosa.
J Antimicrob Chemother. 2025;80:788-796.
PubMed Abstract available

CASTILLO-POLO JA, Hernandez-Garcia M, Maruri-Aransolo A, Morosini MI, et al
Cefiderocol AST in a real-life Klebsiella pneumoniae collection: challenges in the ATU range.
J Antimicrob Chemother. 2025;80:797-801.
PubMed Abstract available

VAN DEN BERG S, Attwood MGL, Griffin P, Sassen SDT, et al
Pharmacodynamics of NOSO-502 studied in vitro and in vivo: determination of the dominant pharmacodynamic index driver.
J Antimicrob Chemother. 2025;80:752-759.
PubMed Abstract available

CHIUSAROLI L, Barbieri E, Dell'Anna L, Petris MG, et al
Efficacy and safety of posaconazole and liposomal amphotericin B use for prophylaxis of invasive fungal infections in a paediatric and young adult haemato-oncological population.
J Antimicrob Chemother. 2025;80:802-809.
PubMed Abstract available

NGUYEN MH, Calado Nogueira de Moura V, Keepers TR, van Ingen J, et al
In vitro susceptibility of 147 international clinical Mycobacterium abscessus isolates to epetraborole and comparators by broth microdilution.
J Antimicrob Chemother. 2025;80:713-716.
PubMed Abstract available

FAROOQ A, Martens M, Kroemer N, Pfaffendorf C, et al
Pharmacokinetic/pharmacodynamic analysis of meropenem and fosfomycin combinations in in vitro time-kill and hollow-fibre infection models against multidrug-resistant and carbapenemase-producing Klebsiella pneumoniae.
J Antimicrob Chemother. 2025;80:701-712.
PubMed Abstract available

HARVEY E, Clegg J, Bresnik M, Blatt E, et al
Development of a novel patient-reported outcome measure for disseminated coccidioidomycosis (valley fever).
J Antimicrob Chemother. 2025;80:657-665.
PubMed Abstract available

TOBIN LA, Abu Sabah E, Lebreton F, Myers GSA, et al
Genomic analysis of early ST32 Acinetobacter baumannii strains recovered in US military treatment facilities reveals distinct lineages and links to the origins of the Tn6168 ampC transposon.
J Antimicrob Chemother. 2025;80:666-675.
PubMed Abstract available

MUSHTAQ S, Vickers A, Doumith M, Garello P, et al
Frequencies and mechanisms of mutational resistance to ceftibuten/avibactam in Enterobacterales.
J Antimicrob Chemother. 2025;80:645-656.
PubMed Abstract available

February 2025

BABIN P, Delbove A, Gousseff M, Gouin JB, et al
Impact of a kidney-sparing protocol for the treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections (CLOXECO): a quasi-experimental study.
J Antimicrob Chemother. 2025 Feb 28:dkaf062. doi: 10.1093.
PubMed Abstract available

SERAPIDE F, Serraino R, Spadafora L, Bernardi M, et al
Clinical characteristics, therapy and outcome of bloodstream infections caused by vancomycin-resistant enterococci: a multicentre clinical experience.
J Antimicrob Chemother. 2025 Feb 25:dkaf055. doi: 10.1093.
PubMed Abstract available

PIMENTEL LR, Lucini F, Silva GAD, Simionatto S, et al
Repurposing tafenoquine as a potent antifungal agent against Candida haemulonii sensu stricto.
J Antimicrob Chemother. 2025 Feb 24:dkaf054. doi: 10.1093.
PubMed Abstract available

LODHIA Z, Costa Da Silva J, Correia C, Cordeiro D, et al
Surveying genetic markers of antibiotic resistance and genomic background in Chlamydia trachomatis: insights from a multiplex NGS-based approach in clinical strains from Portugal.
J Antimicrob Chemother. 2025 Feb 17:dkaf036. doi: 10.1093.
PubMed Abstract available

LIU W, Xu N, Li W, Mak WY, et al
Pharmacokinetics and safety of rifapentine in children: dosing for latent tuberculosis infection.
J Antimicrob Chemother. 2025 Feb 13:dkaf029. doi: 10.1093.
PubMed Abstract available

WERTH BJ, Zhang R, Barreras Beltran IA, Penewit K, et al
Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials.
J Antimicrob Chemother. 2025 Feb 12:dkaf042. doi: 10.1093.
PubMed Abstract available

EDSLEV SM, Aarris M, Nielsen KL, Hertz FB, et al
rpoB mutations and their association with rifampicin resistance in clinical Staphylococcus epidermidis.
J Antimicrob Chemother. 2025 Feb 6:dkaf035. doi: 10.1093.
PubMed Abstract available

XING H, Zhang L, Li C, Schwarz S, et al
Identification of a mepR mutation associated with tigecycline resistance in a clinical Staphylococcus aureus isolate.
J Antimicrob Chemother. 2025 Feb 6:dkaf034. doi: 10.1093.
PubMed Abstract available

DE ANTONIO-CUSCO M, Sorli L, Munoz-Bermudez R, Lopez-Mula C, et al
Penetration of linezolid into the pleural cavity in critically ill patients with proven or suspected Gram-positive bacterial infections: a retrospective pharmacokinetic study.
J Antimicrob Chemother. 2025;80:554-562.
PubMed Abstract available

BROUSSE X, Andry F, Lahouati M, Desmoulin A, et al
Temocillin efficacy against AmpC beta-lactamase-producing Enterobacterales: a relevant alternative to cefepime?
J Antimicrob Chemother. 2025;80:576-582.
PubMed Abstract available

BIANCO G, Boattini M, Lupo L, Ambretti S, et al
In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam: an Italian nationwide multicentre observational study
J Antimicrob Chemother. 2025;80:583-592.
PubMed Abstract available

GOLPARIAN D, Rapp E, Hasmats J, Unemo M, et al
Novel approach using automated target enrichment enables culture-independent accurate whole-genome sequencing of Neisseria gonorrhoeae directly from clinical urogenital and extragenital specimens.
J Antimicrob Chemother. 2025;80:563-566.
PubMed Abstract available

FRATONI AJ, Padgett AM, Roenfanz HF, Duffy EM, et al
Development and confirmation of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin in a standardized neutropenic murine pneumonia model.
J Antimicrob Chemother. 2025;80:478-484.
PubMed Abstract available

JO J, Kim SJ, Kwon KT, Ko KS, et al
Resilience of tigecycline heteroresistance phenotype in Acinetobacter baumannii.
J Antimicrob Chemother. 2025;80:496-502.
PubMed Abstract available

HAENNI M, Chatre P, Drapeau A, Cazeau G, et al
Distinct molecular epidemiology of resistances to extended-spectrum cephalosporins and carbapenems in Enterobacter hormaechei in cats and dogs versus horses in France.
J Antimicrob Chemother. 2025;80:567-575.
PubMed Abstract available

IGARASHI Y, Taguchi K, Enoki Y, Chuang VTG, et al
Simulated achievement rate of beta-lactams/nacubactam treatment in humans using instantaneous MIC-based PK/PD analysis.
J Antimicrob Chemother. 2025;80:547-553.
PubMed Abstract available

CUI XD, Liu SB, Wang RY, He DD, et al
Investigation on the reversal effect of closantel on colistin resistance in MCR-1 positive Escherichia coli based on dose-response relationship.
J Antimicrob Chemother. 2025;80:528-537.
PubMed Abstract available

OSBORN MR, Zuniga-Moya JC, Mazi PB, Rauseo AM, et al
Side effects associated with itraconazole therapy.
J Antimicrob Chemother. 2025;80:503-508.
PubMed Abstract available

KOSTOULIAS X, Fu Y, Morris FC, Yu C, et al
Ceftolozane/tazobactam disrupts Pseudomonas aeruginosa biofilms under static and dynamic conditions.
J Antimicrob Chemother. 2025;80:372-380.
PubMed Abstract available

HUNTER CJ, Marhoffer EA, Holleck JL, Ein Alshaeba S, et al
Effect of empiric antibiotics against Pseudomonas aeruginosa on mortality in hospitalized patients: a systematic review and meta-analysis.
J Antimicrob Chemother. 2025;80:322-333.
PubMed Abstract available

HOFKEN LM, Schauer J, Eisfeld J, Dziobaka J, et al
Characterization of NWM-1, a novel subclass B3 metallo-beta-lactamase found in a clinical isolate of Pseudomonas aeruginosa.
J Antimicrob Chemother. 2025;80:445-451.
PubMed Abstract available

TUMBARELLO M, Giuliano G, Criscuolo M, Del Principe MI, et al
Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study.
J Antimicrob Chemother. 2025;80:386-398.
PubMed Abstract available

January 2025

ABDOLRASOULI A, Curtis CM, Spruijtenburg B, Flores A, et al
Cluster of clonal fluconazole-resistant Candida parapsilosis harbouring Y132F mutation in ERG11 gene in a neonatal ICU in the UK.
J Antimicrob Chemother. 2025 Jan 29:dkaf015. doi: 10.1093.
PubMed

DRONEY M, Reed E, Sarwar S, Coe K, et al
Fluconazole step-down therapy versus echinocandins for the treatment of Candida glabrata invasive candidiasis with candidaemia.
J Antimicrob Chemother. 2025 Jan 28:dkaf026. doi: 10.1093.
PubMed Abstract available

BITTERMAN R, Awwad A, Darawsha B, Dallashi H, et al
Ceftaroline versus vancomycin for methicillin-resistant Staphylococcus aureus bacteraemia, a matched cohort study.
J Antimicrob Chemother. 2025 Jan 28:dkaf009. doi: 10.1093.
PubMed Abstract available

CADDEY B, Shaukat W, Tang KL, Barkema HW, et al
Vancomycin-resistant Enterococcus prevalence and its association along the food chain: a systematic review and meta-analysis.
J Antimicrob Chemother. 2025 Jan 24:dkaf008. doi: 10.1093.
PubMed Abstract available

YANXIA S, Xuewei W, Gang L, Wei J, et al
Analysis on characteristics and multilocus sequence typing of Clostridium perfringens in western China.
J Antimicrob Chemother. 2025;80:216-226.
PubMed Abstract available

ANDES D, Bruggemann RJ, Flanagan S, Lepak AJ, et al
The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics.
J Antimicrob Chemother. 2025;80:18-28.
PubMed Abstract available

BILBAO I, Pineda Abel de la Cruz I, de Asis Carmona-Torre F, Rodriguez-Mateos M, et al
Use of echinocandins combined with clindamycin in Pneumocystis pneumonia: a case series of 14 patients.
J Antimicrob Chemother. 2025;80:102-105.
PubMed Abstract available

CHEN S, Shang Y, Zheng J, Huo F, et al
In vitro monitoring of drug resistance emergence during stepwise induction of bedaquiline and clofazimine, alone and in combination: a phenotypic and genotypic analysis.
J Antimicrob Chemother. 2025;80:262-269.
PubMed Abstract available

ROGER PM, Strzelecki AC, Dautezac V, Hennet MA, et al
Diagnostic uncertainties in patients with bacteraemia: impact on antibiotic prescriptions and outcome.
J Antimicrob Chemother. 2025;80:238-246.
PubMed Abstract available

BALTAS I, Patel T, Soares AL
Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?
J Antimicrob Chemother. 2025;80:59-67.
PubMed Abstract available

HIRABAYASHI A, Yano H, Yahara K, Aoki S, et al
Emergence of the mobile RND-type efflux pump gene cluster tmexCD1-toprJ1 in Klebsiella pneumoniae clinical isolates in Japan.
J Antimicrob Chemother. 2025;80:192-199.
PubMed Abstract available

ANDO N, Mizushima D, Takano M, Mitobe M, et al
Prolonged sitafloxacin and doxycycline combination regimen for treating infections by highly resistant Mycoplasma genitalium.
J Antimicrob Chemother. 2025;80:247-253.
PubMed Abstract available

LONG H, Zhao F, Feng Y, Zong Z, et al
Global emergence of Escherichia coli with PBP3 insertions.
J Antimicrob Chemother. 2025;80:178-181.
PubMed Abstract available

FRATONI AJ, Padgett AM, Duffy EM, Nicolau DP, et al
Establishment of a diverse pheno-genotypic challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa suitable for use in the murine pneumonia model.
J Antimicrob Chemother. 2025;80:154-161.
PubMed Abstract available

ISHAK A, Mazonakis N, Spernovasilis N, Akinosoglou K, et al
Bactericidal versus bacteriostatic antibacterials: clinical significance, differences and synergistic potential in clinical practice.
J Antimicrob Chemother. 2025;80:1-17.
PubMed Abstract available

PARIONA JGM, Vasquez-Ponce F, Pariona EMM, Sousa-Carmo RR, et al
Efficacy of meropenem against ceftazidime-avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114.
J Antimicrob Chemother. 2025;80:162-168.
PubMed Abstract available

O'JEANSON A, Nielsen EI, Friberg LE
Therapeutic drug monitoring (TDM) of beta-lactam/beta-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation study.
J Antimicrob Chemother. 2025;80:79-86.
PubMed Abstract available

December 2024

KIM SH, Kim HM, Chung DR, Ko JH, et al
Synergistic effects of colistin-rifampin-based triple antimicrobial combination therapy against Carbapenem-resistant Pseudomonas aeruginosa: a time-kill assay.
J Antimicrob Chemother. 2024 Dec 31:dkae466. doi: 10.1093.
PubMed Abstract available

KUO CF, Chen YY, Chiu CC, Chiu CW, et al
Comparative in vitro efficacy of AR-12 derivatives against Streptococcus pyogenes.
J Antimicrob Chemother. 2024 Dec 20:dkae462. doi: 10.1093.
PubMed Abstract available

ERSOY SC, Madrigal SL, Proctor RA, Chambers HF, et al
NaHCO3 modulates the bla operon and beta-lactam susceptibility in borderline oxacillin-resistant Staphylococcus aureus (BORSA).
J Antimicrob Chemother. 2024 Dec 20:dkae455. doi: 10.1093.
PubMed Abstract available

HANAI Y, Matsumoto K, Endo A, Hanawa K, et al
Treatment success prediction in patients with methicillin-resistant coagulase-negative staphylococci infections, using vancomycin AUC24/MIC ratio: a multicentre retrospective cohort study.
J Antimicrob Chemother. 2024 Dec 17:dkae442. doi: 10.1093.
PubMed Abstract available

ASSEFA GM, Roberts JA, Aslan AT, Mohammed SA, et al
A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.
J Antimicrob Chemother. 2024 Dec 17:dkae451. doi: 10.1093.
PubMed Abstract available

ZHANG G, Luo Z, Yang Q, Kang W, et al
Establishment of epidemiological cut-off values of etimicin: a new fourth-generation aminoglycoside, against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus.
J Antimicrob Chemother. 2024 Dec 9:dkae414. doi: 10.1093.
PubMed Abstract available

LI X, Qi X, Wang B, Fu L, et al
Efficacy of nintedanib as a host-directed therapy candidate in the treatment of tuberculosis.
J Antimicrob Chemother. 2024 Dec 4:dkae429. doi: 10.1093.
PubMed Abstract available

DOELMAN TA, Adriaens N, Westerhuis BM, Bruisten SM, et al
Phenotypic antibiotic resistance of Mycoplasma genitalium and its variation between different macrolide resistance-associated mutations.
J Antimicrob Chemother. 2024 Dec 4:dkae430. doi: 10.1093.
PubMed Abstract available

WEERDENBURG H, Gwee A, Haeusler GM, Osowicki J, et al
Crushed posaconazole delayed-release tablets for antifungal prophylaxis and treatment in children.
J Antimicrob Chemother. 2024;79:3340-3343.
PubMed Abstract available

GAO Y, Wu T, Pu L, Ji X, et al
Identification of vancomycin exposure target in neonates: how much is enough?
J Antimicrob Chemother. 2024;79:3344-3353.
PubMed Abstract available

FOUAD A, Nicolau SE, Tamma PD, Simner PJ, et al
Differential frequency of persister cells in clinically derived isolates of Pseudomonas aeruginosa after exposure to cefiderocol and ceftolozane/tazobactam.
J Antimicrob Chemother. 2024;79:3236-3242.
PubMed Abstract available

GODRON AS, Amoura A, Pistien C, Birgy A, et al
Inoculum effect of cefiderocol against NDM-1 producing Escherichia coli in vitro and in a murine model of peritonitis.
J Antimicrob Chemother. 2024;79:3323-3331.
PubMed Abstract available

FRATONI AJ, Padgett AM, Duffy EM, Nicolau DP, et al
Quantitative performance of humanized serum and epithelial lining fluid exposures of tigecycline and levofloxacin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia model.
J Antimicrob Chemother. 2024;79:3142-3149.
PubMed Abstract available

FIFER H, Doumith M, Rubinstein L, Mitchell L, et al
Ceftriaxone-resistant Neisseria gonorrhoeae detected in England, 2015-24: an observational analysis.
J Antimicrob Chemother. 2024;79:3332-3339.
PubMed Abstract available

PARDOS SL, Hope W, Kotsaki A, Das S, et al
Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSA.
J Antimicrob Chemother. 2024;79:3303-3312.
PubMed Abstract available

QUINONES-VICO MI, Andrades-Amate M, Fernandez-Gonzalez A, Ubago-Rodriguez A, et al
Antibiotic biocompatibility assay and anti-biofilm strategies for Pseudomonas aeruginosa infection in bioengineered artificial skin substitutes.
J Antimicrob Chemother. 2024;79:3313-3322.
PubMed Abstract available

STERN A, Henig I, Cohen M, Gur I, et al
Impact of discontinuing routine fluoroquinolone prophylaxis in neutropenic allogeneic haematopoietic stem cell transplant recipients: an observational study.
J Antimicrob Chemother. 2024;79:3289-3296.
PubMed Abstract available

STEMKENS R, Lemson A, Koele SE, Svensson EM, et al
A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease.
J Antimicrob Chemother. 2024;79:3100-3108.
PubMed Abstract available

HUANG Y, Liao M, Hu X, Hu H, et al
Advances in the clinical treatment of multidrug-resistant pathogens using polymyxins.
J Antimicrob Chemother. 2024;79:3210-3229.
PubMed Abstract available

ZOHAR I, Ben David D, Schwartz O, Pomerantz A, et al
Amikacin treatment in patients with Enterobacterales bacteraemia: impact of MIC on mortality.
J Antimicrob Chemother. 2024;79:3204-3209.
PubMed Abstract available

VANPARIS O, Oueslati S, Girlich D, Jousset AB, et al
Genetic and biochemical characterization of OXA-1186, a novel OXA-198-type carbapenemase hydrolysing cephalosporins in Citrobacter freundii.
J Antimicrob Chemother. 2024;79:3186-3190.
PubMed Abstract available

ALVAREZ C, Nastro M, Goyheneche B, Potente N, et al
NDM-5-producing Klebsiella pneumoniae ST258 in a university hospital in Argentina.
J Antimicrob Chemother. 2024;79:3174-3177.
PubMed Abstract available

MUDDE SE, Meliefste HM, Ammerman NC, de Steenwinkel JEM, et al
Mycobacterium abscessus strain variability in preclinical drug development: does it really matter?
J Antimicrob Chemother. 2024;79:3169-3173.
PubMed Abstract available

November 2024

LEROY AG, Lemenand O, Thibaut S, Coeffic T, et al
Assessment of co-resistance to antibiotics recommended for acute pyelonephritis among Escherichia coli clinical strains from community- and nursing home-acquired urinary tract infections.
J Antimicrob Chemother. 2024 Nov 29:dkae431. doi: 10.1093.
PubMed Abstract available

LIU Q, Li S, Wang X, Lin Y, et al
Comparative evaluation of eravacycline susceptibility testing methods in 587 clinical carbapenem-resistant Acinetobacter baumannii isolates: broth microdilution, MIC test strip and disc diffusion.
J Antimicrob Chemother. 2024 Nov 21:dkae426. doi: 10.1093.
PubMed Abstract available

HERNANDEZ-LOZANO I, Aranzana-Climent V, Cao S, Matias C, et al
Model-informed drug development for antimicrobials: translational pharmacokinetic-pharmacodynamic modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections.
J Antimicrob Chemother. 2024 Nov 16:dkae409. doi: 10.1093.
PubMed Abstract available

MCGUIRE E, Ready D, Ellaby N, Potterill I, et al
A case of penicillin-resistant group B Streptococcus isolated from a patient in the UK.
J Antimicrob Chemother. 2024 Nov 15:dkae419. doi: 10.1093.
PubMed Abstract available

RAGUNATHAN P, Sae-Lao P, Harikishore A, Daher W, et al
SQ31f is a potent non-tuberculous mycobacteria antibiotic by specifically targeting the mycobacterial F-ATP synthase.
J Antimicrob Chemother. 2024 Nov 5:dkae406. doi: 10.1093.
PubMed Abstract available

AGIBOTHU KUPPARAM HK, Shah I, Chandrasekaran P, Mane S, et al
Pharmacokinetics of anti-TB drugs in children and adolescents with drug-resistant TB: a multicentre observational study from India.
J Antimicrob Chemother. 2024;79:2939-2947.
PubMed Abstract available

COMCE MH, Weersink RA, Beuers U, van Hest RM, et al
Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review.
J Antimicrob Chemother. 2024;79:2750-2761.
PubMed Abstract available

BLOUIN K, Lefebvre B, Trudelle A, Defay F, et al
Neisseria gonorrhoeae treatment failure to the recommended antibiotic regimen-Quebec, Canada, 2015-19.
J Antimicrob Chemother. 2024;79:3029-3040.
PubMed Abstract available

QIAN C, Hu P, Guo W, Han Y, et al
Genome analysis of tigecycline-resistant Acinetobacter baumannii reveals nosocomial lineage shifts and novel resistance mechanisms.
J Antimicrob Chemother. 2024;79:2965-2974.
PubMed Abstract available

LODISE TP, Obi EN, Watanabe AH, Yucel E, et al
Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa.
J Antimicrob Chemother. 2024;79:2954-2964.
PubMed Abstract available

DUKE C, Parker SL, Zam BB, Chiong F, et al
Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment?
J Antimicrob Chemother. 2024;79:2980-2989.
PubMed Abstract available

SANDOE JAT, Grozeva D, Albur M, Bond SE, et al
A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19.
J Antimicrob Chemother. 2024;79:2792-2800.
PubMed Abstract available

SHUKLA A, Rodriguez S, Brennan-Krohn T
Activity of antibiotics against Burkholderia cepacia complex in artificial sputum medium.
J Antimicrob Chemother. 2024;79:2867-2876.
PubMed Abstract available

VENA A, Schenone M, Corcione S, Giannella M, et al
Impact of adequate empirical combination therapy on mortality in septic shock due to Pseudomonas aeruginosa bloodstream infections: a multicentre retrospective cohort study.
J Antimicrob Chemother. 2024;79:2846-2853.
PubMed Abstract available

MA P, Shang S, Liu R, Dong Y, et al
Prediction of teicoplanin plasma concentration in critically ill patients: a combination of machine learning and population pharmacokinetics.
J Antimicrob Chemother. 2024;79:2815-2827.
PubMed Abstract available

YANG F, Sun X, Fu Y, Zhao F, et al
High-level ceftriaxone resistance due to transfer of penA allele 60.001 into endemic gonococcal lineages in Hangzhou, China.
J Antimicrob Chemother. 2024;79:2854-2857.
PubMed Abstract available

COJUTTI PG, Pai MP, Gatti M, Rinaldi M, et al
An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in cri
J Antimicrob Chemother. 2024;79:2801-2808.
PubMed Abstract available

LONGO BM, Trunfio M, Calcagno A
Dual beta-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare.
J Antimicrob Chemother. 2024;79:2731-2741.
PubMed Abstract available

October 2024

AVCU G, Erci E, Bilen NM, Ersayoglu I, et al
Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital.
J Antimicrob Chemother. 2024 Oct 30:dkae387. doi: 10.1093.
PubMed Abstract available

STURARO MC, de Souza GHA, Damaceno NDS, Silva ON, et al
Antimicrobial activity of ceftibuten/polymyxin B combination against polymyxin/carbapenem-resistant Klebsiella pneumoniae.
J Antimicrob Chemother. 2024 Oct 25:dkae382. doi: 10.1093.
PubMed Abstract available

GHAHRAMANI A, Naghadian Moghaddam MM, Kianparsa J, Ahmadi MH, et al
Overall status of carbapenem resistance among clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis.
J Antimicrob Chemother. 2024 Oct 11:dkae358. doi: 10.1093.
PubMed Abstract available

GACHET B, Dechartres A, Senneville E, Robineau O, et al
Systematic review on oral antibacterial relay therapy for acute staphylococcal prosthetic joint infections treated with debridement, antibiotics and implant retention (DAIR).
J Antimicrob Chemother. 2024 Oct 9:dkae347. doi: 10.1093.
PubMed Abstract available

YU L, Han X, Zhang W, Fu Y, et al
The two-component sensor factor envZ influences antibiotic resistance and virulence in the evolutionary dynamics of multidrug-resistant Salmonella enteritidis causing multisite invasive infections.
J Antimicrob Chemother. 2024 Oct 4:dkae355. doi: 10.1093.
PubMed Abstract available

PATAMATAMKUL S
Comment on: Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible Staphylococcus aureus bacteraemia.
J Antimicrob Chemother. 2024 Oct 1:dkae353. doi: 10.1093.
PubMed

COCCITTO SN, Massacci FR, Cinthi M, Albini E, et al
Novel optrA-carrying integrative and conjugative element in a porcine Streptococcus suis, Italy.
J Antimicrob Chemother. 2024 Oct 1:dkae354. doi: 10.1093.
PubMed

ESCRIHUELA-VIDAL F, Fernandez-Hidalgo N, Munoz P, Villamarin M, et al
Infective endocarditis caused by penicillin-resistant viridans group streptococci: a series of nine cases from a Spanish cohort.
J Antimicrob Chemother. 2024 Oct 1:dkae345. doi: 10.1093.
PubMed Abstract available

BUTLER DA, Patel N, O'Donnell JN, Lodise TP, et al
Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature.
J Antimicrob Chemother. 2024;79:2421-2459.
PubMed Abstract available

ALIEVA KN, Golikova MV, Zinner SH
Role of volume and inoculum in MIC assessment: a study with meropenem and Klebsiella pneumoniae.
J Antimicrob Chemother. 2024;79:2698-2707.
PubMed Abstract available

AZAMGARHI T, Scarborough M, Peter-Akhigbe V, Scobie A, et al
Fluoroquinolones in orthopaedic infection: balancing risks and rewards.
J Antimicrob Chemother. 2024;79:2413-2416.
PubMed Abstract available

MASSIP C, Feletti L, Chagneau CV, Dumont Y, et al
Evaluation of several routine methods for fosfomycin and mecillinam susceptibility testing of Enterobacterales urine isolates.
J Antimicrob Chemother. 2024;79:2645-2652.
PubMed Abstract available

DU B, Zhang W, Wang Y, Wu YE, et al
Optimal dosing regimen of caspofungin in adolescents with allogeneic haematopoietic stem cell transplantation.
J Antimicrob Chemother. 2024;79:2678-2687.
PubMed Abstract available

HALLIDAY CL, Tay E, Green W, Law D, et al
In vitro activity of olorofim against 507 filamentous fungi including antifungal drug-resistant strains at a tertiary laboratory in Australia: 2020-2023.
J Antimicrob Chemother. 2024;79:2611-2621.
PubMed Abstract available

CHAFTARI AM, Dagher H, Hachem R, Jiang Y, et al
A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia.
J Antimicrob Chemother. 2024;79:2543-2553.
PubMed Abstract available

GATTI M, Rinaldi M, Laici C, Ambretti S, et al
Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in a case series of orthotopic liver transplant recipients.
J Antimicrob Chemother. 2024;79:2586-2590.
PubMed Abstract available

SEKIGUCHI WK, de Oliveira VF, Cavassin FB, Taborda M, et al
A multicentre study of amphotericin B treatment for histoplasmosis: assessing mortality rates and adverse events.
J Antimicrob Chemother. 2024;79:2598-2606.
PubMed Abstract available

DAVIN-REGLI A, Pages JM, Vergalli J
The contribution of porins to enterobacterial drug resistance.
J Antimicrob Chemother. 2024;79:2460-2470.
PubMed Abstract available

ZHANG XW, Song JJ, Zeng SH, Huang YL, et al
Plasmid-mediated azithromycin resistance in non-typhoidal Salmonella recovered from human infections.
J Antimicrob Chemother. 2024;79:2688-2697.
PubMed Abstract available

LIN YJ, Zou Y, Karlsson MO, Svensson EM, et al
A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB.
J Antimicrob Chemother. 2024;79:2561-2569.
PubMed Abstract available

GONZALEZ-PINTO L, Alonso-Garcia I, Blanco-Martin T, Camacho-Zamora P, et al
Impact of chromosomally encoded resistance mechanisms and transferable beta-lactamases on the activity of cefiderocol and innovative beta-lactam/beta-lactamase inhibitor combinations against Pseudomonas aeruginosa.
J Antimicrob Chemother. 2024;79:2591-2597.
PubMed Abstract available

VAN OS W, Nussbaumer-Proll A, Pham AD, Wijnant GJ, et al
Pharmacokinetic/pharmacodynamic model-based optimization of temocillin dosing strategies for the treatment of systemic infections.
J Antimicrob Chemother. 2024;79:2484-2492.
PubMed Abstract available

HARRYVAN TJ, Schaftenaar E, Franssens BT, Melles DC, et al
EUCAST ciprofloxacin area of technical uncertainty in Escherichia coli and Klebsiella pneumoniae using BD Phoenix and VITEK(R) 2 automated susceptibility systems.
J Antimicrob Chemother. 2024;79:2718-2719.
PubMed

September 2024

SHAN X, Li C, Zhang L, Zou C, et al
poxtA amplification and mutations in 23S rRNA confer enhanced linezolid resistance in Enterococcus faecalis.
J Antimicrob Chemother. 2024 Sep 27:dkae342. doi: 10.1093.
PubMed Abstract available

YANG W, Li X, Chen J, Zhang G, et al
Multicentre evaluation of in vitro activity of contezolid against drug-resistant Staphylococcus and Enterococcus.
J Antimicrob Chemother. 2024 Sep 24:dkae331. doi: 10.1093.
PubMed Abstract available

SAPORTA R, Nielsen EI, Menetrey A, Cameron DR, et al
Model-based translation of results from in vitro to in vivo experiments for afabicin activity against Staphylococcus aureus.
J Antimicrob Chemother. 2024 Sep 24:dkae334. doi: 10.1093.
PubMed Abstract available

FRENS J, Baumeister T, Sinclair E, Zeigler D, et al
Getting rapid diagnostic test data into the appropriate hands by leveraging pharmacy staff and a clinical surveillance platform: a case study from a US community hospital.
J Antimicrob Chemother. 2024;79.
PubMed Abstract available

YUCEEL-TIMUR I, Thierry E, Chainier D, Ndao I, et al
Retrospective evaluation of rapid genotypic ID and phenotypic AST systems on positive blood culture turnaround time and simulated potential impacts on bloodstream infection management.
J Antimicrob Chemother. 2024;79.
PubMed Abstract available

FITTS EC, Dent EA, Burd EM
Validation of short culture method for rapid bacterial identification of blood cultures via matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
J Antimicrob Chemother. 2024;79.
PubMed Abstract available

MACVANE SH, Dwivedi HP
Evaluating the impact of rapid antimicrobial susceptibility testing for bloodstream infections: a review of actionability, antibiotic use and patient outcome metrics.
J Antimicrob Chemother. 2024;79.
PubMed Abstract available

SLAVIN M, Johnson A
JAC Supplement: 'faster ID and AST revolution: how to improve antibiotic use in the critically ill'.
J Antimicrob Chemother. 2024;79.
PubMed

KARLOWSKY JA, Wise MG, Hackel MA, Six DA, et al
Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22.
J Antimicrob Chemother. 2024 Sep 17:dkae329. doi: 10.1093.
PubMed Abstract available

KRUGER-HAKER H, Kostova V, Hanke D, Kaspar H, et al
Genetic basis of macrolide resistance in porcine Pasteurella multocida isolates from the German national resistance monitoring program GERM-Vet 2008-2021.
J Antimicrob Chemother. 2024 Sep 13:dkae316. doi: 10.1093.
PubMed Abstract available

CLARKE F, Grenfell A, Chao S, Richards H, et al
Use of echinocandin outpatient parenteral antimicrobial therapy for the treatment of infection caused by Candida spp.: utilization, outcomes and impact of a change to weekly dosing.
J Antimicrob Chemother. 2024 Sep 11:dkae302. doi: 10.1093.
PubMed Abstract available

ABDELALL LM, Nagy YI, Kashef MT
Restoring vancomycin activity against resistant Enterococcus faecalis using a transcription factor decoy as a vanA operon-inhibitor.
J Antimicrob Chemother. 2024 Sep 10:dkae320. doi: 10.1093.
PubMed Abstract available

WIDERSTROM R, Aarris M, Jacobsson S, Stegger M, et al
Probing fosfomycin's potential: a study on susceptibility testing and resistance in Staphylococcus epidermidis from prosthetic joint infections.
J Antimicrob Chemother. 2024 Sep 6:dkae312. doi: 10.1093.
PubMed Abstract available

BOUTZOUKAS AE, Mackow N, Giri A, Komarow L, et al
Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections.
J Antimicrob Chemother. 2024 Sep 5:dkae306. doi: 10.1093.
PubMed Abstract available

MAILLARD A, Froelicher Bournaud L, Pastre J, Planquette B, et al
Penetration of isavuconazole into the epithelial lining fluid of patients with pulmonary fungal infections. Comment on: 'Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions'
J Antimicrob Chemother. 2024;79:2403-2405.
PubMed

ZHOU J, Xu B, Zheng Y, Huang H, et al
Optimization of oral isavuconazole dose for population in special physiological or pathological state: a physiologically based pharmacokinetics model-informed precision dosing.
J Antimicrob Chemother. 2024;79:2379-2389.
PubMed Abstract available

ABOUELHASSAN Y, Kuti JL, Nicolau DP, Abdelraouf K, et al
Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations.
J Antimicrob Chemother. 2024;79:2227-2236.
PubMed Abstract available

HUANG Y, Cai Z, Lv L, Yue C, et al
Emergence of mcr-8.1 gene coexisting with blaNDM in Citrobacter werkmanii isolated from a chicken farm in China.
J Antimicrob Chemother. 2024;79:2392-2394.
PubMed

BASSETTI M, Cascio A, De Rosa FG, Meschiari M, et al
Management of Clostridioides difficile infection: an Italian Delphi consensus.
J Antimicrob Chemother. 2024;79:2103-2118.
PubMed Abstract available

FEUER L, Frenzer SK, Merle R, Leistner R, et al
Prevalence of MRSA in canine and feline clinical samples from one-third of veterinary practices in Germany from 2019-2021.
J Antimicrob Chemother. 2024;79:2273-2280.
PubMed Abstract available

DAVID A, Golparian D, Jacobsson S, Stratton C, et al
In silico gepotidacin target mining among 33 213 global Neisseria gonorrhoeae genomes from 1928 to 2023 combined with gepotidacin MIC testing of 22 gonococcal isolates with different GyrA and ParC substitutions.
J Antimicrob Chemother. 2024;79:2221-2226.
PubMed Abstract available

JAIDANE N, Vanparis O, Mansour W, Volland H, et al
Evaluation of a novel lateral flow immunochromatographic assay for the rapid detection of KPC, NDM, IMP, VIM and OXA-48 carbapenemases in Gram-negatives.
J Antimicrob Chemother. 2024;79:2396-2399.
PubMed

DIZI ISIK A, Akkoc G, Ergenc Z, Yilmaz S, et al
The use of fosfomycin in infections caused by multidrug-resistant pathogens, especially pneumonia in children: a five-year retrospective single-centre experience.
J Antimicrob Chemother. 2024;79:2179-2185.
PubMed Abstract available

ARCONADA NUIN E, Vilken T, Xavier BB, Doua J, et al
A microbiological and genomic perspective of globally collected Escherichia coli from adults hospitalized with invasive E. coli disease.
J Antimicrob Chemother. 2024;79:2142-2151.
PubMed Abstract available

ABOUELHASSAN Y, Nicolau DP, Abdelraouf K
Defining optimal sulbactam regimens for treatment of Acinetobacter baumannii pneumonia and impact of blaOXA-23 on efficacy.
J Antimicrob Chemother. 2024;79:2306-2316.
PubMed Abstract available

CHEN H, Zhou X, Dai W
Identification of antimicrobial-susceptible Pseudomonas aeruginosa RpoA variant strains through positional conservation pattern.
J Antimicrob Chemother. 2024;79:2298-2305.
PubMed Abstract available

GUO CG, Jiang F, Li Y, Chen Y, et al
Real-world efficacy of second-line therapies for Helicobacter pylori: a population-based study.
J Antimicrob Chemother. 2024;79:2263-2272.
PubMed Abstract available

August 2024

PAPOUSKOVA A, Drabkova Z, Brajerova M, Krutova M, et al
The circulation of methicillin-resistant Staphylococcus aureus between humans, horses and the environment at the equine clinic.
J Antimicrob Chemother. 2024 Aug 30:dkae303. doi: 10.1093.
PubMed Abstract available

ESCRIHUELA-VIDAL F, Chico C, Borjabad Gonzalez B, Vazquez Sanchez D, et al
Effect of a bundle intervention on adherence to quality-of-care indicators and on clinical outcomes in patients with Staphylococcus aureus bacteraemia hospitalized in non-referral community hospitals.
J Antimicrob Chemother. 2024 Aug 30:dkae298. doi: 10.1093.
PubMed Abstract available

HACIOGLU M, Yilmaz FN, Yetke HI, Haciosmanoglu-Aldogan E, et al
Synergistic effects of quorum-sensing molecules and antimicrobials against Candida albicans and Pseudomonas aeruginosa biofilms: in vitro and in vivo studies.
J Antimicrob Chemother. 2024 Aug 30:dkae293. doi: 10.1093.
PubMed Abstract available

Correction to: Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre.
J Antimicrob Chemother. 2024 Aug 28:dkae317. doi: 10.1093.
PubMed

VILLAMARIN M, Fernandez-Hidalgo N, Vinado B, Gonzalez-Lopez JJ, et al
Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre.
J Antimicrob Chemother. 2024 Aug 19:dkae291. doi: 10.1093.
PubMed Abstract available

LUZARRAGA V, Cremniter J, Plouzeau C, Michaud A, et al
In vitro activity of delafloxacin against clinical levofloxacin-resistant Helicobacter pylori isolates.
J Antimicrob Chemother. 2024 Aug 10:dkae269. doi: 10.1093.
PubMed Abstract available

WALTER K, Te Brake LHM, Lemm AK, Hoelscher M, et al
Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures.
J Antimicrob Chemother. 2024 Aug 7:dkae266. doi: 10.1093.
PubMed Abstract available

SCHELLENBERG JJ, Adam HJ, Baxter MR, Karlowsky JA, et al
Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007-21.
J Antimicrob Chemother. 2024 Aug 2:dkae272. doi: 10.1093.
PubMed Abstract available

MEIJS AP, Chaname-Pinedo LE, Deng H, Veldman KT, et al
Association between antimicrobial usage in livestock and antimicrobial resistance in Escherichia coli isolates from human urinary tract infections in the Netherlands, 2009-2020.
J Antimicrob Chemother. 2024 Aug 2:dkae268. doi: 10.1093.
PubMed Abstract available

YANG Q, Li L, Zhao G, Cui Q, et al
Characterization of a multiresistance optrA- and lsa(E)-harbouring unconventional circularizable structure in Streptococcus suis.
J Antimicrob Chemother. 2024 Aug 1:dkae250. doi: 10.1093.
PubMed Abstract available

MAERTENS J, Slavin M, Hoenigl M, Thompson GR 3rd, et al
Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases-a debate.
J Antimicrob Chemother. 2024;79:1786-1793.
PubMed

WIJK M, Gausi K, Malatesta S, Weber SE, et al
The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs.
J Antimicrob Chemother. 2024;79:2022-2030.
PubMed Abstract available

GAMELL A, Velasco-Arnaiz E, Lopez-Ramos MG, Rios-Barnes M, et al
Off-label use of dalbavancin in children: a case series.
J Antimicrob Chemother. 2024;79:2062-2067.
PubMed Abstract available

ONG SWX, Luo J, Fridman DJ, Lee SM, et al
Epidemiology and clinical relevance of persistent bacteraemia in patients with Gram-negative bloodstream infection: a retrospective cohort study.
J Antimicrob Chemother. 2024;79:2053-2061.
PubMed Abstract available

BOUDJELLA-SENHADJI I, Bour M, Potron A, Lorme F, et al
Cross-transmission of Acinetobacter junii carrying blaOXA-58 in a neonatal ICU.
J Antimicrob Chemother. 2024;79:1910-1913.
PubMed Abstract available

SHAH S, Clarke L, Davis MW, Topal JE, et al
Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis.
J Antimicrob Chemother. 2024;79:2017-2021.
PubMed Abstract available

DENG L, Lv LC, Tu J, Yue C, et al
Clonal spread of blaNDM-1-carrying Salmonella enterica serovar Typhimurium clone ST34 and wide spread of IncHI2/ST3-blaNDM-5 plasmid in China.
J Antimicrob Chemother. 2024;79:1900-1909.
PubMed Abstract available

SANCHEZ L, Bitar M, Herail Q, Dorchene D, et al
In vitro and intracellular activity of vaborbactam combined with beta-lactams against Mycobacterium abscessus.
J Antimicrob Chemother. 2024;79:1914-1918.
PubMed Abstract available

ERGUN M, Jansen AME, Hilbrands LB, de Kort E, et al
Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study.
J Antimicrob Chemother. 2024;79:1801-1810.
PubMed Abstract available

YANG YS, Chen HY, Lin IC, Lin MH, et al
Imipenem reduces the efficacy of vancomycin against Elizabethkingia species.
J Antimicrob Chemother. 2024;79:2048-2052.
PubMed Abstract available

UNEMO M, Sanchez-Buso L, Golparian D, Jacobsson S, et al
The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains-phenotypic, genetic and reference genome characterization.
J Antimicrob Chemother. 2024;79:1885-1899.
PubMed Abstract available

DELAHAYE A, Eldin C, Bleibtreu A, Djossou F, et al
Treatment of persistent focalized Q fever: time has come for an international randomized controlled trial.
J Antimicrob Chemother. 2024;79:1725-1747.
PubMed Abstract available

BUCZKOWSKA M, Chattaway MA, Jenkins C, Hungerford D, et al
Linking epidemiological and genomic data in cases of enteric fever in England to inform clinical management and public health action.
J Antimicrob Chemother. 2024;79:1811-1819.
PubMed Abstract available

LEE R, Nho D, Cho SY, Park S, et al
Impact of an antimicrobial stewardship programme on antibiotic utilization and resistance burden in patients with acute leukaemia: an 11-year longitudinal cohort study using interrupted time-series analysis.
J Antimicrob Chemother. 2024;79:1998-2007.
PubMed Abstract available

YASUDA I, Toizumi M, Sando E
Deleterious effects of a combination therapy using fluoroquinolones and tetracyclines for the treatment of Japanese spotted fever: a retrospective cohort study based on a Japanese hospital database.
J Antimicrob Chemother. 2024;79:1962-1968.
PubMed Abstract available

ZHANG MY, Li S, Wang CY, Zhang ZX, et al
A novel antimicrobial peptide S24 combats serious wound infections caused by Pseudomonas aeruginosa and Acinetobacter baumannii.
J Antimicrob Chemother. 2024;79:1951-1961.
PubMed Abstract available

DE LA ROSA-RIESTRA S, Lopez-Hernandez I, Perez-Rodriguez MT, Sousa A, et al
A comprehensive, predictive mortality score for patients with bloodstream infections (PROBAC): a prospective, multicentre cohort study.
J Antimicrob Chemother. 2024;79:1794-1800.
PubMed Abstract available

LOBERTTI CA, Cabezudo I, Gizzi FO, Blancato V, et al
An allosteric inhibitor of the PhoQ histidine kinase with therapeutic potential against Salmonella infection.
J Antimicrob Chemother. 2024;79:1820-1830.
PubMed Abstract available

ZHANG X, Zeng W, Kong J, Huang Z, et al
The prevalence and mechanisms of heteroresistance to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae.
J Antimicrob Chemother. 2024;79:1865-1876.
PubMed Abstract available

HASE R, Sakurai A, Suzuki M, Itoh N, et al
Clinical characteristics and genome epidemiology of Stenotrophomonas maltophilia in Japan.
J Antimicrob Chemother. 2024;79:1843-1855.
PubMed Abstract available

WEBB EJD, Howdon D, Bestwick R, King N, et al
The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study.
J Antimicrob Chemother. 2024;79:1831-1842.
PubMed Abstract available

THEODORE DA, Henneman AD, Loo A, Shields RK, et al
Initial micafungin treatment does not improve outcomes compared to fluconazole treatment in immunocompromised and critically ill patients with candidaemia.
J Antimicrob Chemother. 2024;79:1877-1884.
PubMed Abstract available

FENG Y, Ding P, Shen J, Xu Y, et al
Detection of cfr in Citrobacter braakii and the characterization of two cfr-carrying plasmids from a chicken farm.
J Antimicrob Chemother. 2024;79:2071-2074.
PubMed

DWIBEDY SK, Padhy I, Panda AK, Mohapatra SS, et al
Prevalence of polymyxin-resistant bacterial strains in India: a systematic review and meta-analysis.
J Antimicrob Chemother. 2024;79:1762-1774.
PubMed Abstract available

July 2024

THANASAK J, Wongsurawat T, Jenjaroenpun P, Phumthanakorn N, et al
Characterization of staphylococcal cassette chromosome mec in Staphylococcus haemolyticus ST3 and ST42 isolates from bovine mastitis milk: identification of novel variant in class C1 mec complex.
J Antimicrob Chemother. 2024 Jul 31:dkae242. doi: 10.1093.
PubMed Abstract available

BEADELL B, Yamauchi J, Wong-Beringer A
Comparative in vitro efficacy of antibiotics against the intracellular reservoir of Staphylococcus aureus.
J Antimicrob Chemother. 2024 Jul 29:dkae241. doi: 10.1093.
PubMed Abstract available

ZHOU X, Yang M, Chen F, Wang L, et al
Prediction of antimicrobial resistance in Klebsiella pneumoniae using genomic and metagenomic next-generation sequencing data.
J Antimicrob Chemother. 2024 Jul 19:dkae248. doi: 10.1093.
PubMed Abstract available

JING R, Yi QL, Zhuo C, Kang W, et al
Establishment of epidemiological cut-off values for eravacycline, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Staphylococcus aureus.
J Antimicrob Chemother. 2024 Jul 16:dkae220. doi: 10.1093.
PubMed Abstract available

SHI Q, Ruan Z, Zhang P, Hu H, et al
Epidemiology of carbapenem-resistant Klebsiella pneumoniae in China and the evolving trends of predominant clone ST11: a multicentre, genome-based study.
J Antimicrob Chemother. 2024 Jul 13:dkae227. doi: 10.1093.
PubMed Abstract available

ZHOU H, Buetti N, Perez-Galera S, Bravo-Ferrer J, et al
Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study.
J Antimicrob Chemother. 2024 Jul 11:dkae157. doi: 10.1093.
PubMed Abstract available

BAE J, Park JH, Lee M, Jo HJ, et al
Clinicomicrobiological risk factors for infective endocarditis in viridans group streptococci bacteraemia.
J Antimicrob Chemother. 2024 Jul 8:dkae231. doi: 10.1093.
PubMed Abstract available

SHEEHY J, Scott AP, Henden AS, Kennedy G, et al
Low rates of complications and beta-lactam resistance in viridans group streptococci bloodstream infection among cancer patients receiving chemotherapy.
J Antimicrob Chemother. 2024 Jul 8:dkae209. doi: 10.1093.
PubMed Abstract available

SHAH S, Clarke LG, Ludwig J, Burgdorf S, et al
Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible Staphylococcus aureus bacteraemia.
J Antimicrob Chemother. 2024 Jul 1:dkae198. doi: 10.1093.
PubMed Abstract available

HERMANN L, Schoning V, Drager S, Rentsch K, et al
Population pharmacokinetics of flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection.
J Antimicrob Chemother. 2024 Jul 1:dkae207. doi: 10.1093.
PubMed Abstract available

VALDEZATE S, Medina-Pascual MJ, Villalon P, Garrido N, et al
Co-occurrence of the cephalosporinase cepA and carbapenemase cfiA genes in a Bacteroides fragilis division II strain, an unexpected finding.
J Antimicrob Chemother. 2024;79:1683-1687.
PubMed Abstract available

ZHANG LC, Li QY, Zhang YQ, Shan TC, et al
Population pharmacokinetics of daptomycin in critically ill patients receiving extracorporeal membrane oxygenation.
J Antimicrob Chemother. 2024;79:1697-1705.
PubMed Abstract available

DAABOUL D, Osman M, Kassem II, Yassine I, et al
Neonatal sepsis due to NDM-1 and VIM-2 co-producing Pseudomonas aeruginosa in Morocco.
J Antimicrob Chemother. 2024;79:1614-1618.
PubMed Abstract available

CHARFI R, Tazi A, Sereme Y, Plainvert C, et al
High-level expression of chromosomally encoded SHV-1 beta-lactamase reduces the susceptibility to cefiderocol of clinical isolates of Klebsiella pneumoniae.
J Antimicrob Chemother. 2024;79:1711-1714.
PubMed

CANCELA COSTA A, Kritikos A, Glampedakis E, Da Silva Pereira Clara J, et al
Antifungal drug penetration in soft tissue abscesses: a comparative analysis.
J Antimicrob Chemother. 2024;79:1668-1672.
PubMed Abstract available

IVANOVA M, Ovsepian A, Leekitcharoenphon P, Seyfarth AM, et al
Azithromycin resistance in Escherichia coli and Salmonella from food-producing animals and meat in Europe.
J Antimicrob Chemother. 2024;79:1657-1667.
PubMed Abstract available

BIGHI N, Freitas F, Morgado S, Cipriano R, et al
Deciphering the accessory genome of a novel Klebsiella pneumoniae lineage in the Brazilian Amazon region and its potential contribution to the emergence of a high-risk clone.
J Antimicrob Chemother. 2024;79:1709-1711.
PubMed

CHEN PJ, Tan MC, Huang WC, Hsu SY, et al
The individual contributions of blaB, blaGOB and blaCME on MICs of beta-lactams in Elizabethkingia anophelis.
J Antimicrob Chemother. 2024;79:1577-1580.
PubMed Abstract available

SUBBARAO S, Boyd SE, Basarab M, Riley P, et al
Comment on: In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019).
J Antimicrob Chemother. 2024;79:1715-1716.
PubMed

TAYSI MR, Ocal D, Cicek Senturk G, Caliskan E, et al
Implementation of the EUCAST rapid antimicrobial susceptibility test (RAST) for carbapenemase/ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates, and its effect on mortality.
J Antimicrob Chemother. 2024;79:1540-1546.
PubMed Abstract available

WEERDENBURG H, Walker H, Curtis N, Duffull S, et al
Posaconazole in paediatric malignancy and haematopoietic stem cell transplant: dosing to achieve therapeutic concentration.
J Antimicrob Chemother. 2024;79:1493-1507.
PubMed Abstract available

CADENAS-JIMENEZ I, Saiz-Escobedo L, Carrera-Salinas A, Camprubi-Marquez X, et al
Molecular characterization of macrolide resistance in Haemophilus influenzae and Haemophilus parainfluenzae strains (2018-21).
J Antimicrob Chemother. 2024 Jul 1:dkae214. doi: 10.1093.
PubMed Abstract available

June 2024

CHEN PY, Huang YS, Chuang YC, Wang JT, et al
Implication of genotypes for prognosis of Candida glabrata bloodstream infections.
J Antimicrob Chemother. 2024 Jun 22:dkae200. doi: 10.1093.
PubMed Abstract available

WANG P, Liu S, He X, Miao W, et al
Therapeutic drug monitoring of polymyxin B cerebrospinal fluid concentrations in patients with carbapenem-resistant Gram-negative bacteria-induced central nervous system infection.
J Antimicrob Chemother. 2024 Jun 13:dkae193. doi: 10.1093.
PubMed Abstract available

CHANCHAITHONG P, Chueahiran S, Pinpimai K, Sroithongkham P, et al
Chromosomal and plasmid localization of ileS2 in high-level mupirocin-resistant Staphylococcus pseudintermedius and Staphylococcus aureus isolated from canine and feline origins.
J Antimicrob Chemother. 2024 Jun 12:dkae172. doi: 10.1093.
PubMed Abstract available

WESTON G, Giri A, Komarow L, Ge L, et al
Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales.
J Antimicrob Chemother. 2024 Jun 12:dkae186. doi: 10.1093.
PubMed Abstract available

ALTARAWNEH H, Alhomra T, Alharbi M, Fan Y, et al
Synergistic bactericidal activity of a novel dual beta-lactam combination against methicillin-resistant Staphylococcus aureus.
J Antimicrob Chemother. 2024 Jun 4:dkae165. doi: 10.1093.
PubMed Abstract available

RAHMAT ULLAH S, Jamal M, Rahman A, Andleeb S, et al
Comprehensive insights into Klebsiella pneumoniae: unravelling clinical impact, epidemiological trends and antibiotic-resistance challenges.
J Antimicrob Chemother. 2024 Jun 4:dkae184. doi: 10.1093.
PubMed Abstract available

ELKAYAL O, Mertens B, Wauters J, Debaveye Y, et al
Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study.
J Antimicrob Chemother. 2024 Jun 3:dkae160. doi: 10.1093.
PubMed Abstract available

MOURAD A, Smith AG, Troy JD, Holland TL, et al
Clinical outcomes in patients with piperacillin/tazobactam-non-susceptible but ceftriaxone-susceptible E. coli or K. pneumoniae bloodstream infection.
J Antimicrob Chemother. 2024;79:1456-1461.
PubMed Abstract available

GAUTHIER A, Tlili L, Battu S, Le Moan C, et al
Sedimentation field-flow fractionation for rapid phenotypic antimicrobial susceptibility testing: a pilot study.
J Antimicrob Chemother. 2024;79:1450-1455.
PubMed Abstract available

MARURI-ARANSOLO A, Lopez-Causape C, Hernandez-Garcia M, Garcia-Castillo M, et al
In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain.
J Antimicrob Chemother. 2024;79:1432-1440.
PubMed Abstract available

DURICEK M, Halmova K, Krutova M, Sykorova B, et al
Is shorter also better in the treatment of Clostridioides difficile infection?
J Antimicrob Chemother. 2024;79:1413-1417.
PubMed Abstract available

BIENVENU AL, Cour M, Pavese P, Guichon C, et al
Correlation between antifungal clinical practices and a new clinical decision support system ANTIFON-CLIC(R) for the treatment of invasive candidiasis: a retrospective multicentre study.
J Antimicrob Chemother. 2024;79:1407-1412.
PubMed Abstract available

LIU M, Wang M, Huang M, Gao Q, et al
Iron efflux by IetA enhances beta-lactam aztreonam resistance and is linked to oxidative stress through cellular respiration in Riemerella anatipestifer.
J Antimicrob Chemother. 2024;79:1385-1396.
PubMed Abstract available

LEWIS R, Niazi-Ali S, McIvor A, Kanj SS, et al
Triazole antifungal drug interactions-practical considerations for excellent prescribing.
J Antimicrob Chemother. 2024;79:1203-1217.
PubMed Abstract available

NAVICKAITE I, Holmes H, Dondi L, Randall L, et al
Occurrence and characterization of rmtB-harbouring Salmonella and Escherichia coli isolates from a pig farm in the UK.
J Antimicrob Chemother. 2024;79:1329-1336.
PubMed Abstract available

KOLTE B, Nubel U
Genetic determinants of resistance to antimicrobial therapeutics are rare in publicly available Clostridioides difficile genome sequences.
J Antimicrob Chemother. 2024;79:1320-1328.
PubMed Abstract available

KARAKITSIOS E, Dokoumetzidis A
Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modelling.
J Antimicrob Chemother. 2024;79:1362-1371.
PubMed Abstract available

WANGCHINDA W, Pogue JM, Thamlikitkul V, Leelawattanachai P, et al
Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections.
J Antimicrob Chemother. 2024;79:1372-1379.
PubMed Abstract available

NISSIM Y, LaSala PR, Slain D
A serial passage experiment to assess the development of resistance to ertapenem and meropenem among Enterobacterales.
J Antimicrob Chemother. 2024;79:1463-1466.
PubMed

May 2024

GALAL L, Mohamed HS, Dupont C, Conquet G, et al
Circulation of hypervirulent carbapenem-resistant Klebsiella pneumoniae in humans and fish in Djibouti.
J Antimicrob Chemother. 2024 May 22:dkae144. doi: 10.1093.
PubMed

LEE YL, Wang WY, Ko WC, Hsueh PR, et al
Global epidemiology and antimicrobial resistance of Enterobacterales harbouring genes encoding OXA-48-like carbapenemases: insights from the results of the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme 2018-2021.
J Antimicrob Chemother. 2024 May 17:dkae140. doi: 10.1093.
PubMed Abstract available

MILLS RO, Dadzie I, Le-Viet T, Baker DJ, et al
Genomic diversity and antimicrobial resistance in clinical Klebsiella pneumoniae isolates from tertiary hospitals in Southern Ghana.
J Antimicrob Chemother. 2024 May 16:dkae123. doi: 10.1093.
PubMed Abstract available

MENENDEZ ALVARADO LR, Margulis Landayan A, Williams KN, Frederick CM, et al
Impact of removing ESBL status labelling from culture reports on the use of carbapenems for non-bacteraemic patients diagnosed with ESBL-positive urinary tract infections.
J Antimicrob Chemother. 2024 May 8:dkae135. doi: 10.1093.
PubMed Abstract available

FOUAD A, Nicolau SE, Tamma PD, Simner PJ, et al
Assessing the impact of meropenem exposure on ceftolozane/tazobactam-resistance development in Pseudomonas aeruginosa using in vitro serial passage.
J Antimicrob Chemother. 2024;79:1176-1181.
PubMed Abstract available

ZHENG M, Li FH, Liu J, Li WJ, et al
Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae.
J Antimicrob Chemother. 2024;79:1069-1080.
PubMed Abstract available

GALANI I, Souli M, Katsala D, Karaiskos I, et al
In vitro activity of apramycin (EBL-1003) in combination with colistin, meropenem, minocycline or sulbactam against XDR/PDR Acinetobacter baumannii isolates from Greece.
J Antimicrob Chemother. 2024;79:1101-1108.
PubMed Abstract available

MALLART E, Guerin F, Amoura A, Le Scouarnec M, et al
Impact of the phenotypic expression of temocillin resistance in Escherichia coli on temocillin efficacy in a murine peritonitis model.
J Antimicrob Chemother. 2024;79:1051-1059.
PubMed Abstract available

UNEMO M, Golparian D, Oxelbark J, Kong FYS, et al
Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125-1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea.
J Antimicrob Chemother. 2024;79:1006-1013.
PubMed Abstract available

BERGER A, Badell E, Ahman J, Matuschek E, et al
Corynebacterium diphtheriae and Corynebacterium ulcerans: development of EUCAST methods and generation of data on which to determine breakpoints.
J Antimicrob Chemother. 2024;79:968-976.
PubMed Abstract available

URBANOWICZ P, Izdebski R, Biedrzycka M, Gniadkowski M, et al
VIM-type metallo-beta-lactamase (MBL)-encoding genomic islands in Pseudomonas spp. in Poland: predominance of clc-like integrative and conjugative elements (ICEs).
J Antimicrob Chemother. 2024;79:1030-1037.
PubMed Abstract available

MAESTRO DE LA CALLE G, Velez J, Mateo Flores J, Garcia Barrio N, et al
Assessment of risk-adjusted mortality ratio (RAMR) in bloodstream infections using all-patient refined diagnosis-related groups (APR-DRGs).
J Antimicrob Chemother. 2024;79:1019-1022.
PubMed Abstract available

SPERNOVASILIS N, Tsioutis C
Not surprising: a rebound in antibacterial consumption in Europe, with Cyprus and Greece on the podium.
J Antimicrob Chemother. 2024;79:933-934.
PubMed Abstract available

DUQUE M, Bonnin RA, Dortet L
Comparison of the French novel disc diffusion-based algorithm and the current EUCAST guidelines for the screening of carbapenemase-producing Enterobacterales.
J Antimicrob Chemother. 2024;79:1194-1196.
PubMed

April 2024

PHAISAL W, Albitar O, Chariyavilaskul P, Jantarabenjakul W, et al
Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.
J Antimicrob Chemother. 2024 Apr 25:dkae059. doi: 10.1093.
PubMed Abstract available

STEMKENS R, Mouhdad C, Franssen EJF, Touw D, et al
Ten-year results of an international external quality control programme for measurement of anti-tuberculosis drug concentrations.
J Antimicrob Chemother. 2024 Apr 6:dkae105. doi: 10.1093.
PubMed Abstract available

WANGCHINDA W, Kaye KS, Patel TS, Albin OR, et al
A comparison of strategies for identifying patients at risk for carbapenem-resistant or extended beta-lactam-resistant Pseudomonas aeruginosa.
J Antimicrob Chemother. 2024 Apr 6:dkae104. doi: 10.1093.
PubMed Abstract available

MACFADYEN AC, Paterson GK
Methicillin resistance in Staphylococcus pseudintermedius encoded within novel staphylococcal cassette chromosome mec (SCCmec) variants.
J Antimicrob Chemother. 2024 Apr 2:dkae096. doi: 10.1093.
PubMed Abstract available

VAN INGEN J
Why do we use 100 mg of clofazimine in TB and NTM treatment?
J Antimicrob Chemother. 2024;79:697-702.
PubMed Abstract available

RODRIGUEZ-OCHOA JL, Perez-Palacios P, Merino-Bohorquez V, Ortiz-Padilla M, et al
Evaluation of temocillin efficacy against KPC-2-producing Klebsiella pneumoniae isolates in a hollow-fibre infection model.
J Antimicrob Chemother. 2024;79:784-789.
PubMed Abstract available

REYES BARROS T, Gutierrez Torres W, Garcia Canete P, Cerda Lorca J, et al
Effect of different strategies for excluding duplicate cultures on the correlation between hospital resistance rates and antibiotic consumption.
J Antimicrob Chemother. 2024;79:774-778.
PubMed Abstract available

BOULEKBACHE A, Maldonado F, Kavafian R, Ferry T, et al
Comparison of daptomycin and glycopeptide efficacy and safety for the treatment of Gram-positive infections: a systematic review and meta-analysis.
J Antimicrob Chemother. 2024;79:712-721.
PubMed Abstract available

DAABOUL D, Kassem II, Yassine I, Hamze M, et al
Emergence of NDM-1, VIM-4 and CTX-M-15-co-harbouring Enterobacter xiangfangensis in a bloodstream infection.
J Antimicrob Chemother. 2024;79:923-925.
PubMed

LAI T, Yeo CY, Rockliff B, Stokes M, et al
Therapeutic drug monitoring of liposomal amphotericin B in children. Are we there yet? A systematic review.
J Antimicrob Chemother. 2024;79:703-711.
PubMed Abstract available

March 2024

HARMER CJ, Cahill SM, Kenyon JJ, Hall RM, et al
Aminoglycoside resistance genes in early members of the Acinetobacter baumannii ST78A (SMAL, Italian clone) reside in an IS26-bounded island in the chromosome.
J Antimicrob Chemother. 2024 Mar 26:dkae064. doi: 10.1093.
PubMed Abstract available

GOLPARIAN D, Bazzo ML, Ahlstrand J, Schorner MA, et al
Recent dynamics in Neisseria gonorrhoeae genomic epidemiology in Brazil: antimicrobial resistance and genomic lineages in 2017-20 compared to 2015-16.
J Antimicrob Chemother. 2024 Mar 22:dkae075. doi: 10.1093.
PubMed Abstract available

PITT-KENDALL R, Sun S, Hughes S, Merrick R, et al
Investigating the cause of increased tetracycline-resistant Neisseria gonorrhoeae in England, 2016-20.
J Antimicrob Chemother. 2024 Mar 22:dkae073. doi: 10.1093.
PubMed Abstract available

TESSIER E, Ruffier d'Epenoux L, Lartigue MF, Chaufour L, et al
Comparison of the in vitro activities of delafloxacin and comparators against Staphylococcus epidermidis clinical strains involved in osteoarticular infections: a CRIOGO multicentre retrospective study.
J Antimicrob Chemother. 2024 Mar 20:dkae071. doi: 10.1093.
PubMed Abstract available

PHILIP A, Oueslati S, Villa F, Pannetier C, et al
Development of an ultrafast PCR to detect clinically relevant acquired vancomycin-resistance genes from cultured enterococci.
J Antimicrob Chemother. 2024 Mar 19:dkae062. doi: 10.1093.
PubMed Abstract available

KITTL S, Brodard I, Tresch M, Perreten V, et al
Novel tetracycline resistance gene tet(65) located on a multi-resistance Corynebacterium plasmid.
J Antimicrob Chemother. 2024 Mar 18:dkae066. doi: 10.1093.
PubMed Abstract available

YUNIVITA V, Gafar F, Santoso P, Chaidir L, et al
Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia.
J Antimicrob Chemother. 2024 Mar 9:dkae057. doi: 10.1093.
PubMed Abstract available

ANJUM MF, Duggett N, Sheldon E, Sharma M, et al
Genomics to detect transmission of livestock-associated methicillin-resistant Staphylococcus aureus from UK pigs in abattoirs during slaughter.
J Antimicrob Chemother. 2024 Mar 5:dkae052. doi: 10.1093.
PubMed Abstract available

CHEN RZ, Lu PL, Yang TY, Lin SY, et al
Efficacy of cefoperazone/sulbactam for ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and the factors associated with poor outcomes.
J Antimicrob Chemother. 2024;79:648-655.
PubMed Abstract available

MOREELS N, Boven A, Gressani O, Andersson FL, et al
The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence.
J Antimicrob Chemother. 2024;79:608-616.
PubMed Abstract available

SELBY PR, Heffernan AJ, Yeung D, Warner MS, et al
Population pharmacokinetics of posaconazole in allogeneic haematopoietic stem cell transplant patients.
J Antimicrob Chemother. 2024;79:567-577.
PubMed Abstract available

February 2024

VAN HAL SJ, Jensen SO, Tong SYC, Bentley S, et al
Unravelling the complex interplay between antibiotic consumption and adaptive changes in methicillin-resistant Staphylococcus aureus.
J Antimicrob Chemother. 2024 Feb 27:dkae048. doi: 10.1093.
PubMed Abstract available

FANG ZY, Zhang ZY, Zheng YD, Lei D, et al
Repurposing cinacalcet suppresses multidrug-resistant Staphylococcus aureus by disruption of cell membrane and inhibits biofilm by targeting IcaR.
J Antimicrob Chemother. 2024 Feb 27:dkae051. doi: 10.1093.
PubMed Abstract available

BAYART J, Drouet J, Peycelon M, Mariani P, et al
Temocillin for febrile urinary tract infections caused by ESBL-producing Enterobacteriaceae in children: a monocentric exposed/non-exposed study.
J Antimicrob Chemother. 2024 Feb 27:dkae053. doi: 10.1093.
PubMed Abstract available

COTRONEO N, Stokes SS, Pucci MJ, Rubio A, et al
Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection.
J Antimicrob Chemother. 2024 Feb 23:dkae046. doi: 10.1093.
PubMed Abstract available

JACQUELINE C, Samper-Cativiela C, Monzon Fernandez S, Ugarte-Ruiz M, et al
Phenotypic and genetic characterization of antimicrobial resistance in Salmonella enterica serovar Choleraesuis isolates from humans and animals in Spain from 2006 to 2021.
J Antimicrob Chemother. 2024 Feb 16:dkae029. doi: 10.1093.
PubMed Abstract available

SOMAJO S, Nilsson F, Ekelund O, Unemo M, et al
Detection of antimicrobial resistance in <5 h in Neisseria gonorrhoeae isolates using flow cytometry-proof of concept for seven clinically relevant antimicrobials.
J Antimicrob Chemother. 2024 Feb 9:dkae034. doi: 10.1093.
PubMed Abstract available

ROY S, Morita D, Bhattacharya S, Dutta S, et al
Novel sequence type of carbapenem-resistant Acinetobacter pittii ST1451 with enhanced virulence isolated from septicaemic neonates in India.
J Antimicrob Chemother. 2024 Feb 9:dkae024. doi: 10.1093.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bacterial Infections and Mycoses is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum